ID;Term;Depth;IC Nuno;IC zhou;IC sanchez;IC resnik;IC RZ;IC Rnormalized;IC Nuno org;Annotated Genes Set number
GO:0008584;male gonad development;5.0;1.0;0.7902410118609202;9.628524252492122;50.96471695749156;5.2552850506314295;0.001705743211299806;0.5589965337459591;[HMGB2, LRP2, GATA3, MEA1, GATA1, HOXA11, HOXA10, CTNNA1, PDGFRB, LHCGR, TGFB2, RRM1, BIK, INHBA, EIF2S2, KITLG, SFRP2, NASP, MSH2, KIT, BCL2L1]
GO:1990090;cellular response to nerve growth factor stimulus;6.0;0.9326813400603323;0.7894609826203107;9.5544162803384;97.48528473772916;5.9928839937622085;0.003262744749111514;0.6295966787287501;[CALCA, E2F1, AKT1, ID1]
GO:0032570;response to progesterone;6.0;0.9326813400603323;0.7894609826203107;9.548481544818586;105.99106082751567;6.166155715036245;0.0035474254201351726;0.6384578026126634;[YAP1, GABRB1, TGFB2, TGFB1, CAV1, PTGER2, FOS, THBS1, CLDN4, FOSB, TLR2]
GO:0051091;positive regulation of DNA binding transcription factor activity;11.0;0.811012628672052;0.8379352666656883;9.431813958246067;277.8307104044464;4.2636448815154875;0.00929874384583087;0.650471949850128;[PHB2, TNF, CLU, PYCARD, AKT1, TNFSF11, BTK, PRKCQ, S100A8, CARD11, BEX1, TNFRSF11A, NHLH2, NLRP3, S100A12, FZD1, TGFB1, JUP, NFKB1, IL6, COPS5, JMY, MYD88, CD40, ITGB2, CD36, IL10, MYOCD, EDN1, CHUK, ANXA3, DDX58, NFAM1, IRAK3, TRAF1, GREM1, PSMA6, IL1B, KIT, TLR6, TLR4, LTF, TLR2, NLRC4, NOD2, CD40LG]
GO:0051092;positive regulation of NF-kappaB transcription factor activity;12.0;0.9326813400603323;0.9144609826203107;9.587702257971866;279.4401483168805;4.8283137373023015;0.009352610284359957;0.6950405016553352;[TNF, CLU, PYCARD, TNFSF11, BTK, PRKCQ, S100A8, CARD11, TNFRSF11A, NLRP3, S100A12, TGFB1, NFKB1, MYD88, CD40, ITGB2, CD36, CHUK, IRAK3, TRAF1, GREM1, PSMA6, IL1B, TLR6, TLR4, LTF, TLR2, NLRC4, NOD2, CD40LG]
GO:1903408;positive regulation of sodium:potassium-exchanging ATPase activity;11.0;1.0;0.9324289523296623;9.628524252492122;1737.6104827170566;9.777073627680469;0.05815625910863255;0.9324289523296623;[DNM2]
GO:0071380;cellular response to prostaglandin E stimulus;8.0;1.0;0.875;9.628524252492122;704.3614414198233;6.943860283624253;0.023574343560179453;0.7301093378270707;[P2RY6, PTGER2, PRKCE, AKT1, PTGDR]
GO:0002244;hematopoietic progenitor cell differentiation;4.0;0.811012628672052;0.655506314336026;8.935377071932177;21.066225782797595;5.395046993006588;7.050676185779127E-4;0.5259029541176994;[TOP2A, SPI1, TNFRSF13B, SOX4, PDGFRA, ESCO2, KIT, HOXB4, HOXB3, PLD4, GATA3, JAM3, TGFB1, ACE, INHBA, PTPRC, PTPN6]
GO:1903526;negative regulation of membrane tubulation;7.0;1.0;0.8509193652572005;9.628524252492122;66.13488992371046;9.083926447120524;0.0022134752482098636;0.8154717862087246;[DNM2]
GO:0000188;inactivation of MAPK activity;13.0;0.8436909121759173;0.8844004208555951;9.558319993818873;2610.871803759405;6.518977089658987;0.08738352963975493;0.7959357562962344;[DUSP2, DUSP1, CAV1, DUSP6, DUSP10, PPP2R1A]
GO:0000184;nuclear-transcribed mRNA catabolic process, nonsense-mediated decay;10.0;0.8933024483968273;0.861892236059334;9.57851383191746;717.2549128915896;4.989581884898423;0.0240058764469685;0.6704084614939124;[PPP2R1A, MAGOH, GSPT1, UPF3B, EIF3E]
GO:0048489;synaptic vesicle transport;7.0;0.7671156992804218;0.7344772148974115;9.292052015870908;108.01043080855717;5.459585514144159;0.003615011916085639;0.6301228223472235;[LIN7A, SNCA, SYT2, DNM2]
GO:0045893;positive regulation of transcription, DNA-templated;10.0;0.5159906454948852;0.673236334608363;8.141425192250265;1208.1179641469014;2.4745772039531437;0.04043462102441837;0.5417910051506925;[PID1, SPI1, SPIB, AKT1, MEF2A, MEF2C, PADI2, ATF3, GATA3, GATA1, JUN, JAG1, JUP, NR2F2, COL1A1, HOXC10, FOS, SIRT1, MMP12, CKS2, STAT4, SPP1, ATAD2, PSMC6, PSMC2, LGR4, CCNT2, RUVBL2, ADCYAP1, BLM, FOXO1, ZNF423, NFKB1, CXCL10, CIITA, FHL2, HHEX, PPP1R12A, PEG3, E2F1, E2F2, E2F5, E2F7, PRRX1, POU2AF1, CCNH, TNFSF11, HNF1B, SFRP2, EGR1, EGR2, EGR3, CD28, CD40, HNF4G, BRCA1, BRCA2, CD3D, HNF4A, IL10, RGMA, IL1B, YAP1, SATB2, CD74, FOXA3, IL17A, FOXA2, CD86, CD80, IHH, CCNE1, VDR, HMGA1, INHBA, IL6, BMP2, TCF4, HMGB2, ARHGEF10L, LYL1, NUP62, YWHAH, MYOCD, DDX58, ETV1, CCNA2, GREM1, PSRC1, ELF3, IRF7, CREB5, TAF9, EGF, MAPK14, CD4, RAN, EHF, SERPINE1, MYB, HOXA3, HOXA2, HOXA7, HOXA5, HOXB9, HOXB4, HOXB3, HOXB2, MAML3, HOXB7, HOXB5, NUP85, PRDM16, NKX2-3, FZD1, NFE2, FZD5, FZD8, TGFB1I1, PAX5, PAX2, RARA, ENG, NR1I2, EPCAM, NR1H2, GTF2H1, POU4F1, FOSB, PF4, PLXND1, TNF, CDH1, MEN1, MAP2K2, F2R, DAB2, COPS5, MAFF, BCL3, CYR61, LBH, EMILIN1, RFC1, CHUK, TFDP1, CEBPB, SMARCD3, CEBPE, NOD2, ABLIM3, KLF4, PML, KLF1, KLF5, CHEK1, RPS6KA1, DPF3, SOX7, SOX4, SLC11A1, EBF1, FLT3LG, RUNX2, NIF3L1, IL23A, BEX1, TWIST1, NHLH2, BCL11B, LIF, TOP2A, IFNA2, PRL, EDN1, RHOG, MDFIC, TFEC, TLR4, TLR2, CDX2, CDX1, LILRB1, GRHL2, CAMK4, CAMK1, ARID4A, ARID4B, HOXA11, HOXA10, ADRB2, NLRP3, TGFB2, TGFB1, NR4A2, NFKBIA, NR4A1, NR4A3, SLC40A1, CKAP2, DCN, DNM2, DLL1, LUM, MEIS2, MEIS1, RBMX]
GO:0001701;in utero embryonic development;7.0;1.0;0.8509193652572005;9.628524252492122;22.496195207419138;4.63541007117781;7.529274083310655E-4;0.5879744518658467;[IHH, EDNRA, PDGFRA, TPM1, MSH2, TWIST1, GATA3, GATA1, EPB41L5, CCNB2, CCNB1, PLCG1, MYH10, STIL, EIF2S2, BMP2, MAFF, BCL2L1, PTPRR, TMEM100, HHEX, EDN1, TIE1]
GO:0000060;protein import into nucleus, translocation;9.0;1.0;0.896240625180289;9.628524252492122;93.4429707305496;6.444869117505266;0.0031274521371376313;0.7258315315665724;[TGFB1, RANBP6, PHB2, TNF, NFKBIA, POLA2, BCL6, IFNG, BCL3, AKT1, RAN]
GO:0050679;positive regulation of epithelial cell proliferation;6.0;0.7192862368539868;0.682763431017138;8.647694999480395;65.06748660449396;4.584116776790259;0.002177750219716307;0.5575522577384293;[NRP1, NRP2, ECM1, ITGB3, HMGB2, IHH, TNFAIP3, LAMC1, CDH3, AKT1, IL10, GHSR, ITGA4, ARG1, SIRT1, F3, PAX2, NME1, MMP12, AGTR1, C5AR1, HTRA1, TGFA, TWIST1, NOD2, IQGAP3, CCL5, HMOX1, PLCG1, JUN, TGFB1, EGR3, CAV2, TNFSF12, LAMB1, NR4A1, BMP2, LRG1, CXCL12, NR4A3, ID1, TEK]
GO:0051402;neuron apoptotic process;5.0;0.8259837884571596;0.7032329060895001;9.022388448921806;23.44398779513952;6.113511981550823;7.846491732841165E-4;0.6028862989048107;[NAE1, CIT, BCL2L1]
GO:0070723;response to cholesterol;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;80.91680144162417;6.686031174322154;0.002708212523857764;0.665044257777226;[ABCA1, OSBPL7, TGFB1, INHBA, CCR5]
GO:0065003;protein-containing complex assembly;4.0;0.45485133202666184;0.4774256660133309;6.058991556010752;36.471478728154885;2.4440506132939883;0.0012206675708314864;0.3749888620238313;[, NUP107, PRKACB, CLDN3, PADI4, PDGFC, ABCA1, JUP, FN1, COL1A1, COL1A2, HLA-DRB1, ACHE, ARHGAP6, CHAF1B, CHAF1A, KCND2, ARG1, F5, SLC7A7, KCNA5, CENPA, HLA-DMA, HLA-DMB, DMD, CENPE, CENPF, CENPH, CENPI, CENPK, CENPL, CENPM, GOPC, CENPN, CENPO, KCNG2, GMNN, RUVBL2, RUVBL1, OLFM4, BLM, UQCRB, LIN7A, ACAT1, CXCL12, HLA-DRA, LRRK2, ALAD, VBP1, NDUFC2, ACPP, BDP1, NDUFB7, NDUFB6, HM13, NDUFB4, NDUFB3, NDUFB2, NDUFB1, CCL5, EIF4H, NDUFA8, NDUFA7, NDUFA6, NDUFA3, NDUFA2, IL2RB, CD247, EIF3D, CCNH, TCL1A, SNRPD2, SNRPD1, TNFSF11, FBXO5, SNRPD3, HNF1B, MIF, KCTD12, KCTD15, TGFA, PTK2, CD40, CTSZ, CD3G, CD3E, CD3D, CCT3, CCT2, FCER1G, YAP1, MIS12, CAPG, CCT8, CD74, GCH1, RPA1, RPA3, NDUFAB1, NDUFB10, NDUFB11, CCNB1, H1FX, ECT2, CAV2, UBE2C, CAV1, HMGA1, VIL1, NASP, TCF4, HMGB2, TNFAIP3, LAMC1, NUP62, GREM1, NDUFS8, NDUFS7, NDUFS6, NDUFS4, NDUFS3, NUP54, FBP1, TAF9, SAMHD1, RRM1, EGF, TTC19, TEK, CDA, BIN2, NUP205, ACMSD, HMOX1, NCKAP1L, EHD3, SERPINA1, TK1, BRD2, GSN, GTF2H1, TNF, CLU, DACH1, MEN1, TLE4, SNRPG, SNRPE, SNRPF, ITPR3, NACC2, LSM3, HOPX, CDK1, EMILIN1, ADSL, VWF, TRAF1, PTBP2, MCM2, NLGN1, NLRC4, NOD2, PLN, WASF3, PML, MARCKS, RAD51, P2RX1, IMPDH2, PPP2R1A, MCCC2, COX7A2L, TLN1, MGST1, CD79B, CD79A, VASP, AHCTF1, RAD51C, UQCR10, CTNNA1, NDUFA11, KNTC1, CHRNB4, ADRB2, NLRP3, MYH11, TGFB1, EIF2S1, H2AFX, AXIN2, DNM2, TGFBR3, COL6A2, COL6A1, COLEC12, CAMK2D, HIST1H2BK, HSPD1, REPS2, RBMX]
GO:2000010;positive regulation of protein localization to cell surface;7.0;1.0;0.8509193652572005;9.628524252492122;73.70707873031733;7.004484905440688;0.002466909593039506;0.7091290490632969;[FCER1G, TNF, AKT1, CD247]
GO:0007143;female meiotic nuclear division;7.0;0.8933024483968273;0.7975705894556142;9.474373572664863;65.96656019186406;7.069023426578259;0.0022078414035718876;0.7124295520356204;[PPP2R1A, EREG]
GO:2000370;positive regulation of clathrin-dependent endocytosis;9.0;1.0;0.896240625180289;9.628524252492122;226.36966561352764;8.16763571524637;0.0075763889886123065;0.8139338954918922;[DAB2, DNM2]
GO:0048009;insulin-like growth factor receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;31.002284443533863;7.138016298065211;0.0010376185600805164;0.7400384854347593;[GHR, CRIM1, AKT1, TSC2]
GO:0046622;positive regulation of organ growth;6.0;0.811012628672052;0.7286266269261705;9.360260265897443;146.55654105553208;5.926926025970411;0.004905115536804883;0.6262235851885184;[YAP1, MEF2C, EDN1, MAPK14, TGFBR3, CCNB1, BASP1, CDK1, AKT1]
GO:0008354;germ cell migration;5.0;0.9326813400603323;0.7565816818910864;9.510741216835738;40.540081573954176;7.57984905034425;0.0013568400465755524;0.6778748447945537;[TGFB1, CXADR, KIT]
GO:1900026;positive regulation of substrate adhesion-dependent cell spreading;8.0;1.0;0.875;9.628524252492122;350.51777089970517;6.280566066213989;0.011731514346499779;0.6961884407023742;[DOCK5, NRP1, OLFM4, DNM2, FLNA]
GO:0043113;receptor clustering;6.0;0.7671156992804218;0.7066781622303554;8.992535485772125;42.889232177334534;5.9928839937622085;0.0014354640031724087;0.6295966787287501;[NLGN1, ITGA4, ITGB2, THY1, ITGAL, DNAJA3, FLNA, ITGB7, SHANK3]
GO:0006611;protein export from nucleus;9.0;0.7508913569872202;0.7716863036738992;9.277126365654233;128.4390295807893;5.948432231191374;0.00429873873244698;0.7004437261138039;[, CSE1L, XPO1, NUP62, NUP88, EGR2, TGFB1, STRADB, NUPL2, RAN]
GO:0046626;regulation of insulin receptor signaling pathway;6.0;0.7980440201809971;0.722142322680643;9.260799472366804;66.92878063041714;5.8067817141283475;0.002240046055708086;0.6200793994936333;[PID1, SLA2, GNAI2, SOCS2, SESN3, PRKCD, TSC2, SIRT1, PTPRE, IL1B, PRKCQ]
GO:0006974;cellular response to DNA damage stimulus;4.0;0.5696777571895439;0.534838878594772;7.469040003138749;28.997869804256865;3.161008442547652;9.705326059599744E-4;0.4116541187538124;[SMC3, AKT1, CDCA5, HMOX1, SFN, BARD1, LYN, PLK2, PLK1, CDKN1A, CHAF1B, CHAF1A, CTLA4, ACTL6A, SIRT1, UNG, USP1, PMS1, GTF2H1, FMR1, TNF, PYCARD, RUVBL2, RUVBL1, MACROD2, MEN1, MSH6, MSH2, BLM, CUL5, FOXO1, MAP2K6, FANCI, FANCG, COPS5, BCL6, CNOT3, BCL3, CDK1, BCL2L1, MCM7, EXO1, RFC5, RFC3, RFC4, RFC1, RFC2, SMC1A, TNFRSF1B, TFDP1, DTL, PPP1R15A, RBBP8, POLR2E, E2F1, POLR2I, POLR2J, E2F7, POLR2K, POLR2L, DONSON, PML, RAD50, RAD51, MNDA, SMARCAL1, CCNH, CHEK1, SOX4, ESCO2, MIF, EPHA2, POLA1, TOP2A, FEN1, SUV39H1, BRCA1, BRCA2, RAD51C, SGK1, YAP1, PCNA, RAD54B, RAD54L, GINS2, RPA1, MLH1, RPA3, DCLRE1A, LIG1, FANCD2, PSMD14, CCNB1, HMGA1, JMY, TOPBP1, H2AFX, IRF7, BCL2A1, TAF9, POLD3, POLD1, MAPK14, POLE2]
GO:0046627;negative regulation of insulin receptor signaling pathway;7.0;0.8933024483968273;0.7975705894556142;9.517298617381897;294.34753946768484;6.311337724880743;0.009851547250396369;0.6736814700148209;[PID1, PRKCD, TSC2, SLA2, SOCS2, PTPRE, IL1B, PRKCQ]
GO:0042149;cellular response to glucose starvation;7.0;0.8933024483968273;0.7975705894556142;9.503361109538115;115.90251486529202;6.063501560976162;0.003879152867050031;0.6610071170671804;[SESN3, UPP1, SIK1]
GO:0043117;positive regulation of vascular permeability;6.0;1.0;0.8231203125901445;9.628524252492122;22.58320658440663;7.474488534686424;7.558396008136816E-4;0.7053660038532718;[TGFB1, CXCR2]
GO:1903538;regulation of meiotic cell cycle process involved in oocyte maturation;9.0;0.8933024483968273;0.8428918493787028;9.517298617381897;148.22274980760076;9.083926447120524;0.0049608820442461005;0.8607930461318132;[PPP2R1A]
GO:0051896;regulation of protein kinase B signaling;7.0;0.8933024483968273;0.7975705894556142;9.427853557029971;45.070113835906206;4.498958968449952;0.001508456149618737;0.580996336126719;[CD86, CD80, TNF, FGF5, SESN3, AKT1, TNFSF11, PDGFRB, PDGFRA, IGFBP5, TSC2, EREG, BTC, EPHA2, PDGFA, GATA3, PKHD1, CD19, ICOS, TGFB1, PTK2, LIN28A, CD28, NOX4, HPSE, CCR7, GAB1, SIRT1, F3, VAV1, BANK1, LCK, KIT, CHI3L1, HBEGF, ENG, THBS1, FYN, CCL19, CCL21, TRAT1, EGF, KLF4, KITLG, TEK]
GO:0071480;cellular response to gamma radiation;7.0;1.0;0.8509193652572005;9.628524252492122;60.39874674087868;6.444869117505266;0.0020214916980741903;0.6805102716434839;[YAP1, EGR1, CDKN1A, H2AFX, NOX4, BCL2L1]
GO:0071481;cellular response to X-ray;7.0;1.0;0.8509193652572005;9.628524252492122;60.39874674087868;7.379178354882098;0.0020214916980741903;0.728290889492758;[SFRP2, DNM2]
GO:0045662;negative regulation of myoblast differentiation;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;114.62387697121986;6.518977089658987;0.0038363580074348307;0.6565011041187423;[TGFB1, DLL1, TNF, CXCL10]
GO:0071245;cellular response to carbon monoxide;5.0;1.0;0.7902410118609202;9.628524252492122;234.8296146911994;9.777073627680469;0.007859535870782117;0.7902410118609202;[DNM2]
GO:0043484;regulation of RNA splicing;7.0;0.7671156992804218;0.7344772148974115;9.34084218004034;89.9604162809808;4.901876304479318;0.0030108941738060855;0.601601547428833;[FMR1, MAGOH, PTBP2, ESRP1, RBM38, CLK4, CLK1, RBMX]
GO:0006606;protein import into nucleus;9.0;0.8933024483968273;0.8428918493787028;9.551563211355994;277.5355368998559;5.288437257948329;0.009288864654271135;0.6666915524892495;[NUP107, CSE1L, NUP62, NUP133, SYK, TSC2, MMP12, NUP54, NUP85, NUP88, RANBP2, RANBP1, NUP155, RANBP6, PML, NUP35, RAN]
GO:0050680;negative regulation of epithelial cell proliferation;6.0;0.7307253602413294;0.6884829927108091;8.690254613899192;65.19530579150691;4.989581884898423;0.0021820282128758306;0.5782877622231366;[SPARC, PRL, PTPRK, BRCA2, PHB2, TNF, DUSP10, MEN1, MEF2C, EREG, TGFBR3, CEACAM1, SFRP2, GATA3, THBS1, CCL2, SFN, TGFB2, TGFB1, CAV2, VDR, CAV1, NR2F2, SULF1, SNAI2]
GO:0071364;cellular response to epidermal growth factor stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;97.48528473772916;6.088194173566533;0.003262744749111514;0.63447084575632;[MCM7, AKT1, PLCG1, CAD, PAX2, COL1A1, VIL1, ID1, SNAI2]
GO:0001836;release of cytochrome c from mitochondria;6.0;1.0;0.8231203125901445;9.628524252492122;22.134985108306864;6.686031174322154;7.408380313817617E-4;0.665044257777226;[JUN, BCL2A1, IFI6, SFN, CLU, BCL2L1]
GO:0001837;epithelial to mesenchymal transition;5.0;0.7508913569872202;0.6656866903545304;8.647694999480395;23.145667324477426;5.618190544320798;7.746646556020492E-4;0.5775555375700647;[LOXL2, TMEM100, EPB41L5, TGFB2, TGFB1, TGFBR3, BMP2, SNAI2, ENG]
GO:1990418;response to insulin-like growth factor stimulus;5.0;1.0;0.7902410118609202;9.628524252492122;25.223505691001428;8.67846133901236;8.44208035796484E-4;0.7340579283277371;[AKT1]
GO:0100002;negative regulation of protein kinase activity by protein phosphorylation;11.0;1.0;0.9324289523296623;9.628524252492122;1279.8925717232403;9.777073627680469;0.04283685254704534;0.9324289523296623;[AKT1]
GO:2000249;regulation of actin cytoskeleton reorganization;8.0;0.8933024483968273;0.8216512241984136;9.427853557029971;36.19570401534177;6.221725566191056;0.0012114376393747596;0.6931793347948383;[NRP1, PDGFRA, CSF1R, TGFB1, F11R, HCK, FES, ARHGDIA, NTF3, ARHGDIB, STAP1, TEK]
GO:0032436;positive regulation of proteasomal ubiquitin-dependent protein catabolic process;11.0;0.8259837884571596;0.845420846558242;9.498471124243924;3778.5456327194074;5.334422371190153;0.12646452185682636;0.705231560468336;[LRRK2, CLU, AKT1, CBFA2T3, RNF144B, PLK2, CAV1, PLK1, DAB2]
GO:0018027;peptidyl-lysine dimethylation;10.0;0.8259837884571596;0.8282329060895002;9.423729839846109;368.6575771449121;7.212124270218933;0.012338637336761129;0.7840693824379941;[EHMT2, SUV39H1]
GO:0034614;cellular response to reactive oxygen species;5.0;0.7671156992804218;0.6737988615011312;9.197741336399668;144.094088465717;5.076593261888053;0.004822699464687224;0.5498582273596049;[TNFAIP3, PTPRK, AQP1, IL18RAP, MYB, AKT1, CYP1B1, PDGFRA, ANXA1, CHUK, ARG1, TPM1, PRKCD, FOS, MMP9, SIRT1, PAX2, DNM2, CCNA2, BTK, PCNA, FOXO1, CST3, PDGFD, ECT2, JUN, KLF4, MAPK13, FABP1, IL6, CDK1, EZH2]
GO:0051897;positive regulation of protein kinase B signaling;8.0;1.0;0.875;9.628524252492122;238.41769229280743;4.7664383335842135;0.007979625599047746;0.6187558780415471;[CD86, CD80, TNF, FGF5, TNFSF11, CCR7, PDGFRB, PDGFRA, IGFBP5, GAB1, F3, VAV1, EREG, BTC, LCK, KIT, CHI3L1, HBEGF, ENG, PDGFA, GATA3, THBS1, CD19, FYN, CCL19, ICOS, TGFB1, CCL21, TRAT1, EGF, PTK2, KITLG, LIN28A, CD28, NOX4, TEK, HPSE]
GO:0051898;negative regulation of protein kinase B signaling;8.0;1.0;0.875;9.628524252492122;238.79440420981607;6.063501560976162;0.00799223380789131;0.6850877518099798;[TSC2, KLF4, SIRT1, PKHD1, BANK1, AKT1, EPHA2]
GO:0045429;positive regulation of nitric oxide biosynthetic process;8.0;1.0;0.875;9.628524252492122;658.6394256443023;6.166155715036245;0.02204406883931546;0.6903374900225189;[ITGB2, PTGS2, TNF, CLU, KLRK1, AKT1, CD36, EDN1, AGXT2, KLF4, DNM2, IFNG, IL1B, PTX3, TLR6, TLR4]
GO:0035020;regulation of Rac protein signal transduction;9.0;0.8933024483968273;0.8428918493787028;9.461470167828956;48.758993290020136;7.069023426578259;0.0016319196251719597;0.757750811958709;[ARAP3, DNM2]
GO:0097191;extrinsic apoptotic signaling pathway;6.0;0.8259837884571596;0.7361122068187242;9.223059144383958;51.05903939735586;5.277263957350204;0.0017089000984773794;0.5929998367869052;[FASLG, TNF, IL6R, DCC, DAPK1, TNFRSF1B, IFNG, IL1B, BCL2A1, CASP8AP2, TGFB2, TGFB1, SORT1, TNFSF12, G0S2, TNFRSF10B, INHBA, PML, BCL2L1]
GO:0048812;neuron projection morphogenesis;7.0;0.6547035408479693;0.6782711356811852;8.502512989635898;62.99970935475633;4.360973225476049;0.002108543576046295;0.5739397388140403;[STMN1, EPHB2, EPHB1, MNX1, MEF2A, MAP1B, SDC2, EPB41L3, NCKAP1L, GP5, PTK2, NR4A2, LRFN4, OGN, NRP1, LRRK2, RAC2, DCC, STRADB, PAX2, DNM2, CDH11, SGK1, DSCAML1, SHANK3, NLGN1, LRP2, PAK1, NTF3, SLITRK6, FYN, LINGO1, POU4F1, WEE1]
GO:0043123;positive regulation of I-kappaB kinase/NF-kappaB signaling;8.0;0.8933024483968273;0.8216512241984136;9.517298617381897;239.11083947336738;4.629579150867016;0.008002824611389124;0.6117568930727868;[IL1RN, GOLT1B, TNF, LGALS1, AKT1, TNFSF11, WLS, PRKCE, F2R, CARD11, S100A12, HMOX1, ECT2, NDFIP2, PLK2, TNFRSF10B, CCDC22, MYD88, ECM1, CD40, FASLG, NUP62, CCR7, CD36, CHUK, ZDHHC17, IL1B, TLR6, LTF, NOD2, FLNA, FYN, CCL19, CD74, CCL21, CARD9, CD4, LTBR]
GO:0043488;regulation of mRNA stability;9.0;0.7436939687323844;0.7680876095464813;9.240758721483358;282.23354693635815;4.989581884898423;0.009446102822258332;0.6514080748132811;[FMR1, XPO1, AKT1, SLC11A1, PRKCD, AXIN2, E2F1, RBM38, TNFSF13, MAPK14, MYD88]
GO:0097192;extrinsic apoptotic signaling pathway in absence of ligand;7.0;1.0;0.8509193652572005;9.628524252492122;76.30875120206336;6.375876246018314;0.0025539852293156346;0.6769819729871445;[BCL2A1, DCC, IL1B, BCL2L1]
GO:0060389;pathway-restricted SMAD protein phosphorylation;8.0;1.0;0.875;9.628524252492122;180.75330000196035;7.212124270218933;0.006049650283656873;0.7438283705770736;[TGFBR3, TGFB2, BMP2, TGFB1]
GO:0002576;platelet degranulation;8.0;1.0;0.875;9.628524252492122;39.85546922145481;4.956792062075433;0.0013339266872485146;0.6284905765689417;[ORM1, ECM1, SERPINA1, SPARC, PROS1, ITGB3, ITGA2B, SERPINE1, F13A1, CLU, LAMP2, TIMP3, CD36, TIMP1, VWF, ACTN1, APLP2, ANXA5, ACTN4, F5, MMRN1, PECAM1, SERPING1, TLN1, VCL, STXBP2, PDGFA, THBS1, PSAP, FLNA, LYN, TGFB2, TGFB1, EGF, PCDH7, FN1, LHFPL2, PPBP, SELP, TF, CD9, PF4]
GO:0060709;glycogen cell differentiation involved in embryonic placenta development;5.0;1.0;0.7902410118609202;9.628524252492122;42.294635617598914;9.777073627680469;0.0014155633914202197;0.7902410118609202;[AKT1]
GO:0000165;MAPK cascade;9.0;0.7436939687323844;0.7680876095464813;9.236482164716097;231.45054935470895;4.069963362931594;0.007746441594931149;0.6043787408332628;[IL5RA, TNF, FGF5, TNFSF11, MEN1, PDGFRB, MEF2A, PDGFRA, MEF2C, MAP2K2, PAQR3, EREG, BTC, PDGFA, CSF2RB, IQGAP3, RASGRP4, SPTA1, MAP2K6, TGFB1, PTK2, NFKB1, LAT, LRRK2, CTSH, CCR5, SPTAN1, MAP4K1, CHUK, STRADB, GFRA3, DUSP6, IL1B, KIT, IL3RA, SHANK3, HBEGF, CAMK2D, NOD2, IL2RG, CCL5, CCL2, NCAM1, FYN, EGF, MAPK14, MAPK13, KITLG, IL2RB, TEK]
GO:0043491;protein kinase B signaling;6.0;1.0;0.8231203125901445;9.628524252492122;26.42836680105094;6.250713103064308;8.845336528452411E-4;0.6427820713687392;[CD40, TGFB1, TSC2, TNF, PAX2, TMEM100, CCL5, IL1B, AKT1, CCL2, EPHA2]
GO:0051781;positive regulation of cell division;5.0;0.6763753087927167;0.6284286662572787;8.438940185618286;42.28939918509474;5.358233019883872;0.0014153881327367882;0.5642612976810992;[CXCR5, TGFA, PDGFA, AURKB, FGF5, LBH, RACGAP1, PDGFD, NUP62, PDGFC, ECT2, SVIL, TGFB2, TGFB1, PRKCE, TAS2R13, CDC6, PPBP, CIT, EREG, BTC, IL1B]
GO:0019221;cytokine-mediated signaling pathway;6.0;0.6039883530135606;0.6251144890969248;7.604142487995313;26.50247477320489;3.309374901576116;8.87013979980389E-4;0.49236189895841853;[AKT1, PRKCD, FPR1, GATA3, FLRT2, HMOX1, HLA-DQA2, HLA-DQA1, HLA-DRB4, FN1, COL1A2, HLA-DRB1, CDKN1A, LRRC4, TIMP1, HLA-DPA1, ANXA1, IFNGR1, GPR35, BGN, FOS, SIRT1, F3, FCER2, HLA-DQB1, CCL13, LRRC19, PTAFR, PTGS2, ALOX5, STAT4, CCL19, CCL18, IL12RB1, IL12RB2, CCL23, CCL21, CCL20, HLA-DPB1, PF4, CSF3R, F13A1, IL5RA, CXCL13, TNF, PYCARD, IGHG1, IL13RA2, IL13RA1, IFNA14, IFNA16, IFNA10, CSF1R, TNFRSF11A, FOXO1, SOCS2, TNFRSF17, IFNA21, TNFRSF10C, TNFRSF10B, NFKB1, CXCL10, CXCL11, CXCL12, BCL6, LCN2, HLA-DRA, MYD88, BCL2L1, CIITA, ITGAM, ITGB2, FASLG, TNFSF13B, ITGAX, CHUK, TNFRSF1B, IL3RA, XCL1, BIRC5, LCP1, CX3CR1, NOD2, IL2RG, CCL8, CCL7, CCL5, CCL4, CCL2, CCL1, FYN, FCGR1B, PML, IL2RB, PTPN6, IL1RN, IFI30, IFIT1, TNFSF11, RSAD2, ACSL1, IL1R1, IL1R2, FLT3LG, MIF, EREG, IFI27, IL23A, TWIST1, INPP5D, CCR10, CCR1, EGR1, TNFSF14, TNFSF12, TNFSF13, LIF, PPBP, SDC1, IFNA5, IFNA4, IFNA7, CD40, TNFRSF13B, IFNA2, IFNA8, CCR9, CCR7, CCR6, CD36, CCR5, CCR2, IL10, SYK, GP1BA, IL17RB, VAV1, HCK, CEACAM1, IL1B, KIT, RHOU, CXCR5, IFI6, CXCR4, CXCR6, CXCR1, CXCR2, CD74, PODN, CD40LG, IL18R1, IL17A, CD86, CD80, MPL, IL18RAP, CCRL2, IL6R, PRTN3, CSF2RB, TGFB1, VCAM1, NFKBIA, IL6, CXCL6, CXCL9, CXCL1, CXCL3, CXCL2, CXCL5, GHR, LRRTM4, MMP1, MMP2, IRAK3, MMP9, DCN, IFNG, OAS1, OAS3, LTA, IRF7, CAMK2D, SAMHD1, NCAM1, CD4, LTBR]
GO:0043011;myeloid dendritic cell differentiation;6.0;0.8933024483968273;0.7697715367885581;9.4949928598676;91.1712242271392;6.8867018697843045;0.003051418826107602;0.6753065664753021;[TGFB1, SPI1, CAMK4, LTBR]
GO:0048146;positive regulation of fibroblast proliferation;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;63.74573076450893;5.825829909099042;0.0021335122412550348;0.6210535250702663;[CDKN1A, PDGFA, BMI1, AQP1, CCNB1, PDGFD, MYB, PDGFC, E2F1, PDGFRB, PDGFRA, CD74, JUN, TGFB1, FN1, CDC6, MIF, PML, EREG, BTC, CCNA2, NDUFS4]
GO:0045792;negative regulation of cell size;6.0;1.0;0.8231203125901445;9.628524252492122;29.63014819255531;7.474488534686424;9.916943946027175E-4;0.7053660038532718;[AKT1]
GO:0071276;cellular response to cadmium ion;6.0;1.0;0.8231203125901445;9.628524252492122;78.50383844342444;6.139487467954083;0.0026274528238337297;0.6370939872166814;[JUN, GSN, CHUK, FOS, MMP9, AKT1, HMOX1]
GO:0071158;positive regulation of cell cycle arrest;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;83.12201169572153;5.395046993006588;0.002782018926502022;0.6268223193749;[CDKN1A, BRCA1, SOX4, TFDP1, PCNA, CCNB1, E2F1, SFN, E2F7, TGFB1, PLK2, POU4F1, PML, FAP, CNOT3, CDK1]
GO:0060391;positive regulation of SMAD protein signal transduction;8.0;1.0;0.875;9.628524252492122;234.98809543662418;7.292166977892469;0.007864840078708074;0.747921758369865;[DAB2, TGFB1]
GO:0051306;mitotic sister chromatid separation;4.0;1.0;0.75;9.628524252492122;27.51648075733887;8.67846133901236;9.20951847723215E-4;0.6938169164668168;[PPP2R1A]
GO:0031334;positive regulation of protein complex assembly;6.0;0.612588685250814;0.6294146552155515;8.094593892566166;105.21570715161425;4.251620688548686;0.0035214750303757575;0.5405483923231058;[CYFIP1, CXCL13, TNF, CLU, PYCARD, TCL1A, PRKCE, HNF1B, PFN1, TWIST1, NCKAP1L, VASP, JUN, TGFB1, VIL1, FES, JMY, LMOD1, CCR7, CD36, MMP1, HCK, PSRC1, IFNG, TLR6, LCP1, TLR4, CDH17, PAK1, GSN, CCL21, BIK, NR1H2, RPA1, GTF2H1, PSMC6, RPA3, PSMC2]
GO:2001224;positive regulation of neuron migration;8.0;0.8933024483968273;0.8216512241984136;9.59462270081644;536.247192550588;7.138016298065211;0.017947710943527356;0.7400384854347593;[SEMA6A, FLNA]
GO:2001240;negative regulation of extrinsic apoptotic signaling pathway in absence of ligand;10.0;1.0;0.9152410118609203;9.628524252492122;570.2036429558796;6.221725566191056;0.019084202779771145;0.7334203466557586;[CX3CR1, STRADB, IFI6, TNF, GATA1, IL1B, CTNNA1, AKT1, SNAI2, FYN, PF4, BCL2L1]
GO:0006270;DNA replication initiation;7.0;0.7980440201809971;0.7499413753476991;9.405380701177911;149.0421272461911;6.343086423195323;0.0049883058697239;0.6753050999230941;[GINS2, MCM7, CDC6, POLA1, PURA, POLA2, CDC34, CCNE2, CCNE1, MCM3, MCM4, MCM6, TOPBP1, MCM2]
GO:2001241;positive regulation of extrinsic apoptotic signaling pathway in absence of ligand;10.0;1.0;0.9152410118609203;9.628524252492122;424.359905324836;7.292166977892469;0.01420294413210246;0.7881627702307852;[PPP2R1A, CTNNA1, INHBA, PPP1CA]
GO:0090201;negative regulation of release of cytochrome c from mitochondria;9.0;1.0;0.896240625180289;9.628524252492122;472.8116675549172;6.943860283624253;0.015824581010188264;0.7513499630073597;[AKT1, CLU, BCL2L1]
GO:1903799;negative regulation of production of miRNAs involved in gene silencing by miRNA;10.0;0.8933024483968273;0.861892236059334;9.5758805190067;949.8698671053862;7.697632086000634;0.031791289624636974;0.8088982747154926;[TGFB1]
GO:0006275;regulation of DNA replication;7.0;0.6144040707577935;0.6581214006360973;8.623002386890024;150.73814970462044;5.142344639450834;0.005045070215086414;0.6138991092621975;[SMARCAL1, EHMT2, GMNN, BRCA2, SMC3, DACH1, PPP2R1A, RFC5, RFC3, RFC4, RFC2, ESCO2, SMC1A, EREG, MSH6, DBF4, MSH2, BLM, PCNA, CST3, E2F7, JUN, DONSON, CDC6, STAG2, BCL6, CDK1]
GO:0006397;mRNA processing;8.0;0.7140352122741334;0.7320176061370667;9.165900730544008;234.3529203123214;3.6745150330669007;0.00784358133891816;0.5629148696734654;[CCNH, LGALS3, SNRPD2, SNRPD1, MAGOH, SNRPD3, AURKAIP1, SLBP, UPF3B, GTF2H1, FMR1, SNRPG, SNRPE, SNRPF, SNRPA, LSM5, LSM3, ESRP1, POLR2E, POLR2I, POLR2J, POLR2K, POLR2L, RBM38, ACIN1, RBMX]
GO:0007249;I-kappaB kinase/NF-kappaB signaling;6.0;1.0;0.8231203125901445;9.628524252492122;26.42836680105094;5.602686357784832;8.845336528452411E-4;0.6096419534788213;[TNF, AKT1, CHUK, BTK, TLR8, TLR7, TLR4, CARD11, LY96, CD14, CARD9, NFKB1, NFKBIA, BCL3]
GO:0046889;positive regulation of lipid biosynthetic process;7.0;0.6056485694559711;0.6537436499851861;8.181605269555796;116.24437576905906;5.572381008289503;0.003890594643844275;0.6358911891633434;[FPR2, PTGS2, TNF, CYR61, AKT1, DGAT2, ANXA1, NR1H2, PRKCD, AVPR1A, SORBS1, POR, IFNG, IL1B]
GO:0071260;cellular response to mechanical stimulus;5.0;1.0;0.7902410118609202;9.628524252492122;56.1235610070294;5.420364800990877;0.00187840507897962;0.5674387198563348;[CD40, AQP1, CHEK1, AKT1, IL1B, TLR8, TLR7, TLR5, TLR4, ENG, PTGS2, CASP8AP2, TGFB1, TNFSF14, TNFRSF10B, NFKB1, COL1A1, LTBR, MYD88]
GO:0005978;glycogen biosynthetic process;8.0;1.0;0.875;9.628524252492122;798.0491347435755;6.781341354126479;0.026709986342275536;0.7217981122146513;[AKT1, PGM5]
GO:0044351;macropinocytosis;7.0;0.8653626801206646;0.7836007053175329;9.405380701177911;29.536082298666074;7.8311634786251565;9.88546093788053E-4;0.7514054297404357;[PYCARD, DNM2]
GO:1990314;cellular response to insulin-like growth factor stimulus;8.0;1.0;0.875;9.628524252492122;388.66587636398185;7.57984905034425;0.013008297105323164;0.7626338329336335;[CCNA2, GHSR, TGFB1, FBN1]
GO:0001933;negative regulation of protein phosphorylation;9.0;0.6056485694559711;0.6990649099082746;8.75603614327636;664.693789818838;3.7392027077583316;0.02224670295966317;0.5874636255457587;[PID1, PPP2R1A, AKT1, EPHB2, PAQR3, PRKCD, SFRP2, PRKAR1B, ATF3, TWIST1, THY1, FLRT2, PRKAR2B, SFN, LYN, JUN, PLK1, LIF, NR2F2, PKIG, CDKN1A, PTPRR, LRRC4, TIMP3, DUSP2, DUSP1, BGN, GP1BA, SIRT1, DUSP6, CEACAM1, IL1B, TLR4, ENG, LRRC19, NTF3, DMD, CDKN2C, PODN, NLRP12, PKN1, PYCARD, MEN1, IGFBP3, TSC2, FBLN1, FOXO1, SOCS2, CCNB1, TGFB1, CAV1, PTPRC, LRRK2, TNFAIP3, PTPN22, HHEX, DUSP10, LRRTM4, NUP62, EMILIN1, MYOCD, IRAK3, DCN, GREM1, CSK, SNCA, KLF4, PTPN6]
GO:0016185;synaptic vesicle budding from presynaptic endocytic zone membrane;7.0;1.0;0.8509193652572005;9.628524252492122;41.05829977546847;8.67846133901236;0.0013741843434141336;0.7947362817240173;[DNM2]
GO:0010765;positive regulation of sodium ion transport;8.0;0.7586651285174919;0.754332564258746;9.0306872517365;68.46428617144959;6.375876246018314;0.0022914380443011736;0.701062607729944;[ACTN4, ATP1B2, ATP1B1, DNM2, AKT1, DMD, DRD4]
GO:0050900;leukocyte migration;5.0;0.6023560406934092;0.5914190322076249;8.01908634005802;26.939797568556347;3.896540641279769;9.016507803758389E-4;0.4895102814636384;[IL1RN, CSF3R, PROS1, SIRPG, CXCL13, F11R, CXCL16, VPREB3, EPS8, LGALS3, VPREB1, EDNRB, C3AR1, TNFSF11, IL6R, SLC16A3, CD177, CXADR, ATP1B2, MIF, ATP1B1, CH25H, PRTN3, S100A8, GYPA, CALCA, SDC2, C5AR1, FPR1, FPR3, FPR2, TNFRSF11A, GATA3, CORO1A, NUP85, INPP5D, IGLV1-44, S100A12, NCKAP1L, PLCG1, IGHA1, ELANE, NKX2-3, LYN, CCR1, TGFB2, TGFB1, GPR15, CAV1, FN1, TNFRSF10B, AZU1, DEFA1, PPBP, GP6, SELE, COL1A1, SELP, CXCL10, CXCL11, IL6, COL1A2, SELL, SDC1, IGKV3-20, IGHM, CXCL6, CXCL9, ITGAM, ITGB3, ITGB2, CXCL1, SLC7A11, CXCL3, ITGAL, CXCL2, TREM1, CXCL5, PDE4B, ITGAX, OLR1, FFAR2, CCR7, ITGB7, CCR6, CCR5, CD34, CCR2, IL10, ANXA1, FCER1G, SYK, ITGA4, MMP1, MMP9, VAV1, SLC7A5, ZAP70, HCK, CEACAM1, SLC7A7, SLC7A8, CEACAM6, LCK, IL1B, CEACAM5, KIT, PECAM1, XCL1, CEACAM8, CX3CR1, CCL13, CXCR5, CXCR4, CCL8, IGKC, CXCR1, CCL7, EPCAM, CCL5, CXCR2, CCL4, CCL2, CCL1, FYN, CD58, CCL19, CCL18, JAM2, JAM3, CD74, CCL23, CCL21, CCL20, CD2, NLRP12, PTPN6, TEK, CD244, PF4]
GO:0030111;regulation of Wnt signaling pathway;6.0;0.5902001590945054;0.6182203921373972;7.99439372746765;41.8512380110395;4.069963362931594;0.0014007232725606145;0.5312584282431182;[PPP2R1A, RUVBL2, RUVBL1, SOX7, SOX4, WLS, TLE4, RNF43, TSC2, HNF1B, SFRP4, DEPDC1B, SFRP2, DAAM2, NAIP, APCDD1, FOXO1, FZD1, EGR1, JUP, FZD5, CAV1, NFKB1, COL1A1, BMP2, DAB2, SNAI2, CDK14, LRRK2, TNFAIP3, HHEX, AXIN2, AES, GREM1, MDFIC, PFDN5, TLR2, YAP1, LRP1, FRZB, CTHRC1, EGF, TMEM64, MAPK14, SULF1, PPP1CA, SULF2, LGR4]
GO:0001938;positive regulation of endothelial cell proliferation;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;87.3065775231622;5.277263957350204;0.0029220725788817177;0.6207988894539612;[NRP1, NRP2, ECM1, ITGB3, HMGB2, AKT1, HMOX1, PLCG1, IL10, GHSR, JUN, EGR3, ITGA4, ARG1, CAV2, TNFSF12, SIRT1, F3, NR4A1, BMP2, LRG1, CXCL12, AGTR1, TEK]
GO:0035924;cellular response to vascular endothelial growth factor stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;62.59148538135601;6.599019797332524;0.00209488068703431;0.6605944919115335;[NR4A1, NRP1, EGR3, ANXA1, VCAM1, AKT1, GAS1, MAPK14]
GO:0010763;positive regulation of fibroblast migration;8.0;0.9326813400603323;0.8413406700301662;9.567899630675686;201.49065414776382;7.379178354882098;0.006743710864509851;0.7523715242355574;[PAK1, TGFB1, PRKCE, AKT1, THBS1, SLC8A1]
GO:0070734;histone H3-K27 methylation;11.0;0.9326813400603323;0.8987696223598284;9.59462270081644;767.5947827162904;7.379178354882098;0.02569070658705971;0.8098004765652196;[EHMT2, EZH2]
GO:0051315;attachment of mitotic spindle microtubules to kinetochore;4.0;0.8933024483968273;0.6966512241984136;9.292052015870908;27.921945865447032;7.379178354882098;9.345223999966889E-4;0.6273715242355574;[CENPE, SEH1L, MIS12, NUF2, KIF2C, NDC80, MAD1L1]
GO:0007050;cell cycle arrest;6.0;0.811012628672052;0.7286266269261705;9.292052015870908;55.61614271062087;4.7664383335842135;0.0018614222452456451;0.5668761906316916;[CDKN1A, DUSP1, STRADB, MSH2, IFNG, RRAGD, GAS1, PPP1R15A, CUL5, THBS1, GAS2L1, MAP2K6, BARD1, TGFB2, TGFB1, CDKN2C, DHCR24, INHBA, PML, FAP, JMY]
GO:0021915;neural tube development;5.0;1.0;0.7902410118609202;9.628524252492122;33.009488292418915;6.409777797693995;0.0011047978665365144;0.618037346520142;[STIL, TGFB1, NUP133, GRHL2]
GO:0008380;RNA splicing;8.0;0.7248374789738407;0.7374187394869203;9.182237149863703;117.47952805794706;3.8501476017100584;0.003931934079388465;0.5718967274016261;[LGALS3, SNRPD2, PPP2R1A, SNRPD1, MAGOH, SNRPD3, UPF3B, FMR1, SNRPG, SNRPE, SNRPF, SNRPA, LSM5, LSM3, ESRP1, POLR2E, POLR2I, POLR2J, POLR2K, POLR2L, RBM38, ACIN1, RBMX]
GO:0007173;epidermal growth factor receptor signaling pathway;9.0;0.7763722522362496;0.7844267512984139;9.040737587590003;32.38857880465376;5.788089581116195;0.0010840165847632744;0.6922437955322635;[TGFA, SLC30A10, EPS8, EFEMP1, REPS2, AKT1, PLCG1, TGFB1, EGF, GAB1, PTK2, EREG, BTC, VIL1, KIF16B, FES, HBEGF]
GO:0045600;positive regulation of fat cell differentiation;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;114.26328322821418;5.71663061713405;0.00382428925936973;0.6154690682008903;[CEBPB, PTGS2, FRZB, PRDM16, AKT1, TMEM64, MAPK14, BMP2, KLF5, SFRP2]
GO:1901666;positive regulation of NAD+ ADP-ribosyltransferase activity;6.0;1.0;0.8231203125901445;9.628524252492122;49.122279745261444;8.67846133901236;0.0016440784958923031;0.7669372290569613;[TGFB1]
GO:0003374;dynamin family protein polymerization involved in mitochondrial fission;8.0;1.0;0.875;9.628524252492122;46.126504921393284;7.57984905034425;0.0015438126085597365;0.7626338329336335;[DNM2]
GO:1903721;positive regulation of I-kappaB phosphorylation;10.0;1.0;0.9152410118609203;9.628524252492122;1064.5221611191064;8.67846133901236;0.035628598724910615;0.8590579283277371;[AKT1]
GO:0043666;regulation of phosphoprotein phosphatase activity;9.0;0.7436939687323844;0.7680876095464813;9.328419660041783;158.30216566976694;5.058574756385375;0.005298231022267458;0.6549363734696205;[TNF, PPP2R1A, PDGFRB, PPP1R12A, FCRL3, IGFBP3, PPP1R15A, GNAI2, NCKAP1L, FKBP1B]
GO:0045725;positive regulation of glycogen biosynthetic process;10.0;1.0;0.9152410118609203;9.628524252492122;1082.4256827352704;7.004484905440688;0.036227813481280256;0.7734506956670166;[AKT1, SORBS1]
GO:0043547;positive regulation of GTPase activity;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;49.33745512692421;3.758480413184235;0.001651280222271285;0.5153291757075998;[F11R, TIAM2, DEPDC1B, RIN2, LLGL2, EPHA2, THY1, RACGAP1, NCKAP1L, JUN, EZH2, ARHGAP9, DENND1B, NRP1, CD40, ARHGAP6, ARHGAP4, CCR7, RHOG, GMIP, VAV1, DEPDC1, CCL13, NTF3, CCL19, CCL18, RANBP2, RANBP1, CCL23, CCL21, CCL20, DLC1, SIPA1, CXCL13, RGS1, ARHGDIA, ARHGDIB, F2R, TSC2, ADCYAP1, ACAP1, PRTN3, ARHGAP19, ARHGAP15, ADAP2, ECT2, EVI5, CAV2, ARHGAP25, TBCK, ARHGAP30, ARHGAP11A, DOCK4, LRRK2, TAGAP, ARHGEF12, TBC1D9, ARAP3, ARAP1, AXIN2, ALDH1A1, XCL1, ASAP2, CCL8, CCL7, CCL5, CCL4, CCL2, CCL1]
GO:0032801;receptor catabolic process;6.0;0.8436909121759173;0.7449657686781032;9.34084218004034;102.12013474586499;6.518977089658987;0.003417869007789623;0.6565011041187423;[RNF43, TGFB1, KIF16B, AP2M1]
GO:0030509;BMP signaling pathway;11.0;0.7090535922965819;0.7869557484779532;9.133828010656014;282.55034729266697;5.202362649177086;0.009456705845082177;0.6984780201431826;[FSTL1, TMEM100, EGR1, TGFB2, TGFB1, USP9Y, RUNX2, RGMA, TGFBR3, BMP2, ID1, ENG]
GO:0019049;evasion or tolerance of host defenses by virus;9.0;0.660418147677249;0.7264496990189135;8.890925309361343;177.3716437189982;8.390779266560578;0.005936469291159198;0.8253454670833372;[TGFB1]
GO:0050999;regulation of nitric-oxide synthase activity;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;24.724602712185703;6.039404009397101;8.275102020790521E-4;0.6319757144917204;[CNR1, AKT1, GCH1, CAV1, DNM2, FCER2, IL1B]
GO:0031397;negative regulation of protein ubiquitination;10.0;0.7508913569872202;0.7906866903545304;9.372590878354922;529.4632463014641;5.572381008289503;0.01772065836772442;0.7002128357670632;[TNFAIP3, AKT1, FBXO5, SOX4, PRKCE, FYN, CAV1, MAD2L1]
GO:0071456;cellular response to hypoxia;6.0;1.0;0.8231203125901445;9.628524252492122;103.24589989147204;5.104244793218563;0.0034555473540902374;0.5841516286869992;[SUV39H1, MPL, PHB2, SLC8A1, AQP1, AKT1, EDN1, KCND2, PRKCE, SIRT1, CCNA2, TWIST1, PTGS2, CCNB1, E2F1, HMOX1, FABP1]
GO:0032007;negative regulation of TOR signaling;8.0;0.8933024483968273;0.8216512241984136;9.517298617381897;239.487551390376;5.926926025970411;0.008015432820232688;0.6781032725983739;[SESN3, TSC2, SIRT1, SIK1]
GO:2001244;positive regulation of intrinsic apoptotic signaling pathway;9.0;0.7671156992804218;0.7797984748205;9.413412872875176;596.4251749563025;5.75172193694532;0.019961813857978603;0.6903839525180965;[PLEKHF1, NACC2, CAV1, SIRT1, LCK, ATF3, S100A8, NOX1, BCL2L1]
GO:0030501;positive regulation of bone mineralization;7.0;0.9326813400603323;0.8172600352873667;9.55953138100517;171.85898464291293;6.221725566191056;0.005751965552953692;0.6690987000520388;[MEF2C, TGFB1, ADRB2, SLC8A1, BMP2, FAM20C, LTF]
GO:0010575;positive regulation of vascular endothelial growth factor production;6.0;1.0;0.8231203125901445;9.628524252492122;64.54350789155374;6.481236761676141;0.002160213123744424;0.6545710619905948;[TGFB1, C5AR1, BRCA1, PTGS2, SULF1, SULF2, IL1B, C3AR1, CYP1B1, HPSE, NOX1]
GO:0007182;common-partner SMAD protein phosphorylation;8.0;1.0;0.875;9.628524252492122;180.75330000196035;7.9853141584524145;0.006049650283656873;0.7833693374183408;[TGFB1, PML]
GO:0010592;positive regulation of lamellipodium assembly;9.0;1.0;0.896240625180289;9.628524252492122;310.04759849733875;6.8867018697843045;0.010377014096983099;0.7484268790654467;[RAC2, DNM2]
GO:0007183;SMAD protein complex assembly;6.0;1.0;0.8231203125901445;9.628524252492122;44.51706700895919;7.8311634786251565;0.0014899461700306506;0.7236063770733796;[TGFB1]
GO:1904262;negative regulation of TORC1 signaling;9.0;1.0;0.896240625180289;9.628524252492122;287.3302539485202;7.069023426578259;0.00961668501921688;0.757750811958709;[SESN3]
GO:0007186;G-protein coupled receptor signaling pathway;5.0;0.5508212674310002;0.5656516455764204;7.20077601654407;23.17027026302992;2.605416804911955;7.75488093814194E-4;0.4234821484283897;[MRGPRF, EDNRA, EDNRB, GPR171, C3AR1, AKT1, PROK2, HOMER3, PRKACB, PTGDR, TAS2R10, TAS2R13, TAAR2, TRHR, EREG, TIAM2, SFRP4, ADCY9, SFRP2, AGTR1, FPR1, FPR3, FPR2, OR7D2, CCR10, CCR1, ABCA1, FZD1, GPR15, FZD5, OR2J2, FZD8, AZU1, NMBR, PPBP, MARCO, PNOC, OR7C2, GPR18, GPR19, GPR25, GABRB1, GRIK3, ADM, CD3E, AKAP12, CCR9, RAC2, FFAR2, CCR7, CCR6, CCR5, CCR2, EDN1, GPR37, ANXA1, GPR35, RHOG, GPBAR1, TACR3, AGTRAP, PTH2R, GP1BA, AVPR1A, SORCS3, VAV1, MC3R, CCL13, PTGER2, PTAFR, CXCR5, CXCR4, CXCR6, GNAI1, GNAI2, FGD3, FGD4, CXCR1, FRZB, NPY, CXCR2, FLNA, CCL19, GABRE, CCL18, GPR157, P2RY13, GABBR1, CCL23, CCL21, SORT1, GABRA5, CCL20, P2RY14, GPR6, RAMP1, LGR4, F2RL3, PF4, CHRM2, CHRM1, CELSR1, CXCL13, CXCL16, RGS1, CCRL2, PDGFRB, CD97, GHSR, LHCGR, SPNS3, APLP2, F2R, NPY1R, DGKZ, ADCYAP1, SPNS1, OR2C3, CALCA, SUCNR1, CALCRL, GPR87, C5AR1, GPR85, ITPR3, GPR84, ADRB2, GPR82, HRH4, PSAP, ECT2, DRD4, HTR1E, CAV1, GPR98, CXCL10, CXCL11, CXCL12, GNB2, OR7E24, TAS2R7, CXCL6, CXCL9, OR1G1, CXCL1, CXCL3, CXCL2, CXCL5, GRM5, CA2, PDE4B, PTGIR, ARHGEF12, GLP2R, OR2H1, XCL1, CX3CR1, LRP1, OR1E1, P2RY6, CCL8, PLN, CCL7, CNR1, P2RY2, OR2W1, CCL5, CCL4, CCL2, S1PR3, OR12D3, CCL1, S1PR5, SLC12A2, TSHR, OR11A1, PTPN6]
GO:0033572;transferrin transport;10.0;1.0;0.9152410118609203;9.628524252492122;96.80640656383476;6.193554689224359;0.0032400233075819585;0.731979686697602;[STEAP3, TFRC, DNM2, TF]
GO:0043552;positive regulation of phosphatidylinositol 3-kinase activity;11.0;0.9326813400603323;0.8987696223598284;9.597752593825367;732.6859750532908;6.375876246018314;0.024522340210466318;0.7584915600596062;[LYN, PDGFRB, PDGFRA, TGFB1, CCL21, FPR2, NOD2, PTK2, FGR, KIT, CCR7, TEK, CCL19]
GO:0006893;Golgi to plasma membrane transport;7.0;0.8933024483968273;0.7975705894556142;9.510741216835738;32.11060110714162;5.845247994956144;0.0010747129213912287;0.6498456195510879;[GOLPH3L, DNM2, GOPC, CCDC22]
GO:0042220;response to cocaine;6.0;0.9326813400603323;0.7894609826203107;9.5544162803384;106.24722930474235;6.343086423195323;0.0035559991485312878;0.647506047256038;[CCNA2, CNR1, TACR3, DNM2]
GO:1901796;regulation of signal transduction by p53 class mediator;7.0;0.7192862368539868;0.710562483684194;9.117698628726131;45.070113835906206;4.948759890378168;0.001508456149618737;0.6039991761920099;[CHEK1, AKT1, MIF, SIRT1, TAF9, TWIST1, AURKB, TP53BP2, CD74, MAPK14, POU4F1, PML, JMY, SNAI2, TAF5]
GO:0043312;neutrophil degranulation;9.0;1.0;0.896240625180289;9.628524252492122;132.80263134205524;3.603287523778533;0.004444784556409926;0.5805129167163294;[CDA, CYFIP1, ABCA13, PSMD3, C3AR1, PRSS3, PRKCD, RNASE3, RNASE2, BIN2, PADI2, FPR1, FPR2, GNS, S100A12, NCKAP1L, ELANE, JUP, FUCA1, AZU1, LYZ, TCN1, ARHGAP9, SIGLEC9, SERPINA1, PYGL, TIMP2, OLR1, ANXA3, ARG1, NFAM1, PSMA5, PSMA2, SERPINB10, GRN, PTAFR, ALOX5, METTL7A, GSN, LRG1, SLCO4C1, PSMC2, SIGLEC5, ATP8A1, HP, APEH, PYCARD, CLEC5A, LAMP2, CD177, OLFM4, CLEC4D, SLC27A2, S100A8, BRI3, HVCN1, GPR84, PSAP, ATP8B4, DEFA4, DEFA1, NFKB1, PTPRC, LCN2, HPSE, ITGAM, ITGB2, ITGAL, FCAR, ALAD, FCGR3B, GM2A, ITGAX, DSP, CR1, NDUFC2, TNFRSF1B, PECAM1, BPI, ACPP, FGL2, TTR, FCGR2A, P2RX1, IMPDH2, PTPN6, MNDA, FOLR3, LGALS3, ANPEP, SLC11A1, MIF, CHIT1, SLPI, CRISPLD2, STXBP2, MGST1, CD14, PRG2, NBEAL2, PPBP, BST1, VNN1, ORM1, CTSZ, CTSS, GLIPR1, CTSH, CTSG, CD36, SPTAN1, CAMP, CD33, CTSB, CCT2, FCER1G, MME, RHOG, CEACAM1, CEACAM6, CEACAM8, TLR2, LILRA3, CST3, CXCR1, CXCR2, CD58, CCT8, LILRB2, LILRB3, QPCT, CD68, MPO, PLAU, CD97, CHRNB4, CD93, OSCAR, DOK3, PRTN3, VCL, PSMD14, C5AR1, MGAM, SELL, MS4A3, TNFAIP6, CRISP3, CXCL1, SIRPB1, HK3, PLAUR, MMP8, MMP9, FGR, CHI3L1, LTF, CLEC12A, RETN, MAPK14, S100P, PTX3]
GO:0043433;negative regulation of DNA binding transcription factor activity;11.0;0.811012628672052;0.8379352666656883;9.468181602416943;278.0076986152632;4.753193106834193;0.00930466748196786;0.6755074688592472;[TNFAIP3, PHB2, PYCARD, CYP1B1, HAVCR2, MEN1, IL10, CHUK, IRAK3, SIRT1, SFRP4, XCL1, SIK1, TWIST1, PKHD1, FLNA, NLRP3, HMOX1, WFS1, KLF4, NFKBIA, NLRP12, ID1, CCDC22, EZH2, FOXA2]
GO:0060312;regulation of blood vessel remodeling;5.0;0.8259837884571596;0.7032329060895001;9.377209824211215;28.902788426864877;7.57984905034425;9.673503178263487E-4;0.6778748447945537;[CST3, CEACAM1, TGFB1]
GO:0006897;endocytosis;5.0;0.6324783794010864;0.6064802015614634;8.088079211544972;26.35802846831835;3.582668236575797;8.821794921490709E-4;0.47345883209051776;[SPARC, TFRC, CLEC10A, ICAM3, KIAA1109, DPYSL2, CUBN, SLC11A1, HSPG2, RIN2, FPR2, CD14, IGHA1, ELANE, MSR1, MARCO, DENND1B, ACHE, ADM, ASGR1, ASGR2, STAB1, CD36, ANXA1, FCER1G, SYK, ANXA3, NME1, CEACAM1, RARA, RHOU, CD302, CD5L, TMPRSS2, IGKC, CXCR1, CXCR2, SORT1, LILRB1, SIGLEC1, RAMP1, SCARB2, NCF4, HP, LY75, CXCL16, LOXL2, PYCARD, AP2M1, CD93, TSC2, PRTN3, CALCRL, PLD4, ADRB2, CORO1A, IGLV1-44, CD163, SYT2, CAV2, CAV1, LRP1B, MARCH3, DAB2, IGKV3-20, LRP12, BCL2L1, LRRK2, ITGB3, ITGB2, ITGAL, GHR, ITGA4, DNM2, PECAM1, COLEC12, NLGN1, LRP1, CEBPE, LRP2, DLL1, FCGR1B, ATP9A, SNCA, NLGN4Y, CD6, CD9, FCGR2B]
GO:0006412;translation;7.0;0.8653626801206646;0.7836007053175329;9.510741216835738;402.5585345733233;4.39257856489138;0.01347327187300917;0.5755560373415389;[AKT1, GSPT1, COPS5, EIF4H, NDUFA7]
GO:2000727;positive regulation of cardiac muscle cell differentiation;9.0;0.8436909121759173;0.8180860812682478;9.4949928598676;667.9527156383532;6.8867018697843045;0.02235577627399952;0.7484268790654467;[GREM1, MEF2C, MYOCD, EDN1, TGFB1]
GO:0071560;cellular response to transforming growth factor beta stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;97.48528473772916;5.788089581116195;0.003262744749111514;0.6191234829421188;[CX3CR1, EPB41L5, PDGFD, FYN, MEF2C, EDN1, POSTN, TGFB1, ARG1, CAV1, COL1A1, COL4A2, NOX4, XCL1, FBN1]
GO:0051056;regulation of small GTPase mediated signal transduction;7.0;0.6799073451904818;0.6908730378524415;8.647694999480395;45.070113835906206;4.018171853803189;0.001508456149618737;0.5564088607247961;[EPS8, ARHGDIA, STMN1, ARHGDIB, EPHB2, PDGFRB, F2R, TSC2, TIAM2, DEPDC1B, ARHGAP19, ARHGAP15, RASGRP4, RACGAP1, ECT2, ABCA1, TGFB2, ARHGAP25, ARHGAP30, BCL6, GPR18, ARHGAP9, ARHGAP11A, NRP1, ARHGEF10L, ARHGAP6, ARHGAP4, NUP62, PSD3, TAGAP, RAC2, TIMP2, RALGPS2, PLEKHG1, ARHGEF12, GPR35, RHOG, ARAP3, RHOH, ARAP1, GMIP, VAV1, DNM2, RHOU, FBP1, FGD3, FGD4, EPS8L1, EPS8L3, COL3A1, DLC1, SIPA1, F2RL3]
GO:0045066;regulatory T cell differentiation;7.0;0.8653626801206646;0.7836007053175329;9.485423408851448;66.99450330244977;8.390779266560578;0.002242245734394454;0.7800242071602487;[TGFB1, CD28]
GO:0032355;response to estradiol;5.0;0.9326813400603323;0.7565816818910864;9.523163736834295;74.25476231829794;4.940791720728991;0.0024852400698459885;0.542913330229313;[IHH, BRCA2, CTGF, RUVBL2, PDGFRB, IL10, GHSR, POSTN, ANXA1, DUSP1, TACR3, CCNA2, IL1B, RARA, PCNA, ABCB4, PTGS2, SOCS2, CST3, RBBP8, TGFB1, NR2F2, POU4F1, COL1A1, GH1, CD4, KIF18A, EZH2]
GO:0072656;maintenance of protein location in mitochondrion;7.0;1.0;0.8509193652572005;9.628524252492122;48.00389740763819;8.16763571524637;0.0016066472455308106;0.7686126355688037;[AKT1]
GO:0030178;negative regulation of Wnt signaling pathway;7.0;0.6835726970475526;0.6927057137809769;8.781226392104918;188.91844949246428;4.7018998124466425;0.006322930488946581;0.591374740326424;[RUVBL2, TLE4, RNF43, TSC2, AXIN2, AES, GREM1, SFRP4, SFRP2, PFDN5, LRP1, APCDD1, FOXO1, FRZB, CTHRC1, FZD1, EGR1, CAV1, TMEM64, MAPK14, BMP2, DAB2, SNAI2]
GO:0072655;establishment of protein localization to mitochondrion;7.0;0.7671156992804218;0.7344772148974115;9.117698628726131;87.58932464406844;5.587418885654044;0.002931535870562561;0.6366602269110988;[HSPD1, AKT1]
GO:0010469;regulation of signaling receptor activity;6.0;0.5916390046238794;0.6189398149020842;7.95454781892045;48.619731222684926;3.470798340732454;0.0016272586491059737;0.5006171011438312;[IL1RN, SERPINE1, CXCL13, TNF, CTGF, CXCL16, FGF5, EFEMP1, PLAU, VSTM1, TNFSF11, FAM3D, EPHB2, PHLDA2, MEF2C, IFNA14, IFNA16, DAPK1, PRKCE, PRKCD, FLT3LG, MIF, EREG, BTC, ADCYAP1, SFRP2, IL23A, IFNA10, CALCA, TGFA, PDGFA, ADRB2, PDGFD, PDGFC, IFNA21, TGFB2, TGFB1, JAG1, TNFSF14, TNFSF12, TNFSF13, LIF, INHBA, PPBP, GH1, CXCL10, CXCL11, IL6, BMP2, CXCL12, PNOC, OGN, CD320, FBN1, IFNA5, IFNA4, NRP1, CXCL6, IFNA7, CXCL9, IFNA2, CXCL1, FASLG, ADM, PRL, CXCL3, IFNA8, CXCL2, CXCL5, TNFSF13B, TIMP1, IL10, EDN1, GREM1, IFNG, IL1B, LTA, XCL1, SHANK3, HBEGF, CCL13, NLGN1, GRN, CLEC12B, RETN, CCL8, TTR, GPNMB, CCL7, CCL5, NPY, CCL4, NTF3, SPP1, CCL2, CCL1, CCL19, CCL18, CMTM8, CCL23, CCL21, EGF, CCL20, KITLG, CD40LG, CMTM2, FCGR2B, PF4, IL17A]
GO:0032233;positive regulation of actin filament bundle assembly;10.0;0.8933024483968273;0.861892236059334;9.533214072687796;256.92976895603965;5.734022359845919;0.008599208145178776;0.7084791820027498;[NRP1, SYNPO2, ARHGEF10L, CTGF, PAK1, FLNA, TPM1, VIL1, ID1, NOX4, PFN1]
GO:0050766;positive regulation of phagocytosis;8.0;0.7671156992804218;0.7585578496402109;9.34084218004034;175.32691305650852;5.825829909099042;0.005868033996023792;0.6729332124801218;[SIRPG, TNF, SIRPB1, PYCARD, STAP1, CCL2, NCKAP1L, CD36, FCER1G, SLC11A1, AZU1, DNM2, IL1B, PTX3, FCGR2B]
GO:0072659;protein localization to plasma membrane;6.0;0.7866048967936545;0.7164227609869718;9.260799472366804;65.42666064804821;4.677207199856271;0.002189771451718415;0.5623129063031725;[PLEKHF1, F11R, TNF, CDH1, FCER1G, GOLPH3L, TTC7B, ATP1B1, PKP3, TSPAN33, EPB41L3, FLNA, TSPAN5, JUP, TSPAN15, EHD3, RAMP1]
GO:0050765;negative regulation of phagocytosis;8.0;0.8436909121759173;0.7968454560879586;9.503361109538115;175.4194889364855;7.069023426578259;0.005871132427413739;0.7365101867784198;[TGFB1, PRTN3, CSK, FCGR2B, TLR2]
GO:0016567;protein ubiquitination;9.0;0.6913464685778243;0.7419138594692012;8.996001693748612;153.79381005389072;3.300101264790787;0.005147340417060716;0.5650079573320931;[AKT1, CDCA3, BARD1, HACE1, PLK1, SIRT1, RNF43, FBXW2, CUL5, SOCS2, MARCH3, MARCH1, BIRC5, DTL, NLRC4, RNF24, CDC20, HERC5, SKP2, CDC34, NAIP, BRCA1, BMI1, RNF144B, PDZRN3, PCNA, KLHL14, UBE2C, UBE2M, TNFAIP3, HIST1H2BK]
GO:0090307;mitotic spindle assembly;8.0;1.0;0.875;9.628524252492122;186.05212215721153;6.193554689224359;0.006226997092562797;0.6917386748366816;[KIF11, CDC20, FLNA, BIRC5]
GO:0035066;positive regulation of histone acetylation;11.0;0.811012628672052;0.8379352666656883;9.498471124243924;1302.9179711131005;6.444869117505266;0.043607491943109866;0.7620198587159455;[TGFB1, LIF, GATA3, BRCA1, IL1B, RUVBL2]
GO:0014003;oligodendrocyte development;5.0;1.0;0.7902410118609202;9.628524252492122;34.09911675737102;6.558197802812269;0.001141266750656509;0.6256275524841266;[LYN, EIF2B3, TGFB1, GSN, CD9, WASF3]
GO:1905000;regulation of membrane repolarization during atrial cardiac muscle cell action potential;11.0;0.8933024483968273;0.8790801765280758;9.571365838652174;341.26330238295816;9.777073627680469;0.01142177561372519;0.9324289523296623;[FLNA]
GO:0045742;positive regulation of epidermal growth factor receptor signaling pathway;8.0;0.8259837884571596;0.7879918942285797;9.417215158824915;233.1839134473908;6.280566066213989;0.0078044557311868065;0.6961884407023742;[EGF, PLAUR, TGFA, FASLG, ARAP1, MMP9, EREG, NUP62, AKT1]
GO:1902895;positive regulation of pri-miRNA transcription by RNA polymerase II;12.0;1.0;0.9481203125901445;9.628524252492122;1721.2385553242598;6.599019797332524;0.0576083054325737;0.7855944919115336;[JUN, TGFB2, BMP2, TGFB1, KLF5, SPI1, PRL, FOS]
GO:1901203;positive regulation of extracellular matrix assembly;7.0;1.0;0.8509193652572005;9.628524252492122;123.61133381433942;8.16763571524637;0.004137160099788013;0.7686126355688037;[TGFB1, EMILIN1]
GO:0043687;post-translational protein modification;7.0;0.6467165523344657;0.6742776414244334;8.507933057105237;151.15475272427284;3.8799197600437285;0.005059013543235805;0.5493386422205575;[LGALS1, PSMD3, SKP2, ESCO2, MXRA8, SPARCL1, SDC2, FN1, TF, SERPINA1, TIMP1, F5, PSMA5, PSMA6, PSMA3, PSMA4, PSMA2, FAM20C, FSTL1, CST3, SPP1, PSMC6, PSMC2, NUCB1, TNC, MEN1, IGFBP5, APLP2, IGFBP3, FBXW2, PSMD14, CUL5, SOCS2, IGFBP7, NAE1, WFS1, IL6, COPS5, CCDC22, UBE2M, FBN1, LAMC1, CYR61, VCAN, DTL, LAMB1]
GO:1900118;negative regulation of execution phase of apoptosis;8.0;0.8653626801206646;0.8076813400603323;9.420884887713877;104.8373729998345;6.686031174322154;0.00350881252679432;0.7169239451870815;[BCL2L1]
GO:0070262;peptidyl-serine dephosphorylation;8.0;1.0;0.875;9.628524252492122;179.24922260518233;7.292166977892469;0.005999310166768488;0.747921758369865;[PPP2R1A, DUSP1, PPP1CA]
GO:0071230;cellular response to amino acid stimulus;6.0;0.7140352122741334;0.6801379187272112;8.962045319014338;283.89643900763554;5.6339389012889365;0.009501758323378283;0.6112402100070131;[CEBPB, ABCB4, TNF, SESN3, PDGFD, PDGFC, FYN, PDGFRA, MMP2, COL1A1, COL3A1, COL1A2, COL4A1, COL5A2, COL6A1, RRAGD, BCL2L1]
GO:0000086;G2/M transition of mitotic cell cycle;5.0;1.0;0.7902410118609202;9.628524252492122;43.44612409677276;4.981283082083729;0.0014541026745458175;0.5449840603320351;[CDKN1A, PPP2R1A, SKP2, TUBG1, CDC25A, CIT, DNM2, CCNA2, MELK, PKMYT1, CCNB2, CCNB1, PRKAR2B, PLK1, WEE1, CDK1, CDK14]
GO:0071233;cellular response to leucine;7.0;1.0;0.8509193652572005;9.628524252492122;346.4947445545057;7.57984905034425;0.011596867275214601;0.738553198190834;[SESN3, RRAGD]
GO:0042482;positive regulation of odontogenesis;7.0;0.8436909121759173;0.7727648213451592;9.474373572664863;103.86878039186215;7.379178354882098;0.0034763946038822383;0.728290889492758;[BMP2, EDN1, TGFB1, CD34]
GO:0000082;G1/S transition of mitotic cell cycle;5.0;1.0;0.7902410118609202;9.628524252492122;42.752976916212816;5.142344639450834;0.0014309036622044387;0.5532207558659172;[CDKN1A, MCM7, GMNN, SKP2, CDC25A, DBF4, CDC34, CCNE2, CCNE1, MCM3, MCM4, RHOU, MCM6, BCAT1, MCM2, CUL5, PRIM1, IQGAP3, GSPT1, RBBP8, RANBP2, RANBP1, CDKN2C, PLK2, RPA1, CDC6, INHBA, POLA1, POLA2, WEE1, NASP, POLE2, RPA3]
GO:0071479;cellular response to ionizing radiation;6.0;0.8933024483968273;0.7697715367885581;9.446202695698167;48.660440229648614;5.602686357784832;0.0016286211429333208;0.6096419534788213;[YAP1, CDKN1A, BLM, FIGNL1, ECT2, EGR1, TGFB1, H2AFX, MAPK14, SIRT1, DNM2, RAD51, SFRP2, NOX4, BCL2L1]
GO:2000179;positive regulation of neural precursor cell proliferation;6.0;0.8259837884571596;0.7361122068187242;9.186691500213083;64.30534655244489;6.015873511986907;0.00215224207805574;0.6307723637598831;[LYN, CX3CR1, SMARCD3, EGF, CTSZ, LRP2, GNAI2, FLNA]
GO:0032465;regulation of cytokinesis;6.0;0.5930994877375815;0.6196700564589352;8.140447197062288;31.798591743249187;5.358233019883872;0.0010642702487719462;0.5971405984103235;[AHCTF1, BRCA2, NUP62, PRKCE, TAS2R13, CIT, CXCR5, AURKB, RACGAP1, ECT2, E2F7, SVIL, PLK1, CDC6, PRC1, BCL2L1]
GO:0071356;cellular response to tumor necrosis factor;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;4.973052582947213;0.0027327542132076126;0.5774424529526606;[PID1, BRCA1, PYCARD, TCL1A, AKT1, EDN1, POSTN, CHUK, SIRT1, CHI3L1, XCL1, CCL13, CALCA, GATA3, ADAMTS12, THBS1, CCL8, CCL7, CCL5, CCL4, CCL2, CCL1, CD58, CCL19, CCL18, CCL23, VCAM1, CCL21, CCL20, MAPK14, NFKB1, COL1A1]
GO:0007281;germ cell development;4.0;0.8653626801206646;0.6826813400603323;9.34084218004034;71.68419734523428;4.759793790865545;0.0023992055735558276;0.4934160758179115;[AKT1, MSH2, KIT, RARA, JAM3, MLH1, FANCG, LIN28A, BCL2L1]
GO:1903077;negative regulation of protein localization to plasma membrane;8.0;0.8436909121759173;0.7968454560879586;9.4949928598676;218.53196919702376;6.686031174322154;0.007314068343020746;0.7169239451870815;[TGFB1, PID1, DAB2, GOPC, CSK, AP2M1, BCL2L1]
GO:0070935;3'-UTR-mediated mRNA stabilization;11.0;1.0;0.9324289523296623;9.628524252492122;1969.4104306254499;6.8867018697843045;0.06591439475871723;0.7846152062148197;[RBM38, MAPK14, MYD88]
GO:0070936;protein K48-linked ubiquitination;11.0;1.0;0.9324289523296623;9.628524252492122;157.60047254366168;5.8650506222523235;0.00527474598481953;0.7323679139043926;[TNFAIP3, HACE1, UBE2C, CDC34]
GO:0038203;TORC2 signaling;7.0;1.0;0.8509193652572005;9.628524252492122;27.12151398160788;7.9853141584524145;9.077326651865194E-4;0.7592887026755414;[SESN3]
GO:0030163;protein catabolic process;5.0;0.6347111282356054;0.607596575978723;8.35223078658656;135.66522553384723;3.7109655375767217;0.004540593007841691;0.48001996203013964;[, CDC20, AKT1, SKP2, CDC34, ADAMTS12, ELANE, PLK1, SIRT1, PSMA5, PSMA6, CEACAM1, PSMA3, PSMA4, PSMA2, PSMC6, PSMC2, MAD2L1, BUB1B, ABHD12, LAMP2, AP2M1, PSMD14, CCNB1, WFS1, UBE2C, CDK1, HPSE, AURKB, RNF24, PML]
GO:1903078;positive regulation of protein localization to plasma membrane;8.0;0.8436909121759173;0.7968454560879586;9.434368238051164;218.50214452761784;5.845247994956144;0.00731307013817619;0.6739262542938873;[LRP1, TREM2, AKT1, EPHB2, PLS1, PRKCE, RHOG, SORBS1, VIL1, IFNG, EPHA3, EPHA2]
GO:1900126;negative regulation of hyaluronan biosynthetic process;9.0;1.0;0.896240625180289;9.628524252492122;591.2837729800367;8.67846133901236;0.019789735760794357;0.8400575416471059;[TGFB1]
GO:0002031;G-protein coupled receptor internalization;8.0;0.9326813400603323;0.8413406700301662;9.567899630675686;66.79409571189065;7.379178354882098;0.0022355382726935618;0.7523715242355574;[ADM, DNM2]
GO:0031929;TOR signaling;6.0;0.8653626801206646;0.7558016526504768;9.377209824211215;26.42836680105094;6.518977089658987;8.845336528452411E-4;0.6565011041187423;[GATA3, SESN3, AKT1, CARD11]
GO:1901215;negative regulation of neuron death;6.0;0.7586651285174919;0.7024528768488905;9.05316010758856;58.54459561550999;4.545965010825883;0.001959434928535777;0.5556011746527726;[AKT1, MEF2C, F2R, MSH2, NAIP, C5AR1, SLC30A10, CORO1A, HMOX1, FZD1, JUN, WFS1, NR4A2, NR4A3, BCL2L1, NRP1, LRRK2, CHL1, CD34, IL10, SIRT1, CEBPB, LRP1, GPNMB, NTF3, CCL2, FYN, SNCA, GABRA5, POU4F1]
GO:0006754;ATP biosynthetic process;11.0;0.7043150770688792;0.7845864908641018;9.424925297250882;8670.873920960137;5.433268205826786;0.29020634685463875;0.7102865410484548;[ATP5J, ATP5I, ATP5H, ATP5O, COX5B, ATP5L, HK3, CYC1, TGFB1, BPGM, ATP5J2]
GO:0006874;cellular calcium ion homeostasis;9.0;0.6324783794010864;0.7124798148808322;8.83001655627435;287.08247441589424;3.7781370657337865;0.009608392061246992;0.5894547304232562;[CXCL13, SLC8A1, EDNRA, EDNRB, CCRL2, C3AR1, PROK2, PTGDR, PDGFRA, PRKCE, F2R, ATP1B1, ADCYAP1, AGTR1, CALCA, C5AR1, FPR1, FPR3, ITPR3, FPR2, THY1, PKHD1, CD19, HRH4, PLCG1, ELANE, CCR10, DRD4, CCR1, TGFB1, WFS1, VDR, CAV1, CXCL10, CXCL11, CXCL12, PTPRC, CD24, GPR18, CXCL9, CD40, ATP2A3, FASLG, ADM, GRM5, JPH2, CCR9, CCR7, CCR6, CD36, CCR5, CCR2, TRPC7, CD52, PTGIR, EDN1, TRPC3, GPR35, TRPC1, AVPR1A, LCK, IL1B, XCL1, CX3CR1, SLC24A2, SLC24A1, CCL13, SLC24A4, CAMK2D, PTGER2, CXCR5, CXCR4, KCNA5, CXCR6, ATP2C2, CCL8, PLN, CXCR1, CCL7, SV2A, CCL5, CXCR2, S1PR3, CCL1, CCL19, GPR157, SNCA, CCL23, CCL21, TMEM64, GPR6, PML, P2RX5, CD4, XK, FKBP1B, GRINA, F2RL3]
GO:0006511;ubiquitin-dependent protein catabolic process;8.0;0.7369933605727446;0.7434966802863723;9.190269321560967;156.4521708431119;3.582668236575797;0.005236313360306564;0.5582178202295975;[, CDC20, PSMD3, SKP2, CDC34, HACE1, PLK1, TGFB1I1, SIRT1, PSMA5, PSMA6, RNF144B, PSMA3, PSMA4, PSMA2, USP1, RANBP2, RANBP1, USP9Y, PSMC6, PSMC2, MAD2L1, BUB1B, RNF43, PSMD14, CUL5, CCNB1, WFS1, UBE2C, CDK1, DTL, AURKB, RNF24, PML]
GO:0042130;negative regulation of T cell proliferation;9.0;0.7763722522362496;0.7844267512984139;9.424925297250882;581.9323154417883;5.734022359845919;0.01947675089275457;0.6894787953221185;[CD86, CD274, CEBPB, CD80, IHH, LRRC32, GPNMB, CTLA4, HAVCR2, IL10, TGFB1, ARG1, PAWR, LILRB1, PDCD1LG2, LILRB2, XCL1, PTPN6, PDE5A, MAD1L1]
GO:0097711;ciliary basal body-plasma membrane docking;5.0;1.0;0.7902410118609202;9.628524252492122;21.38880323109876;5.223196736079928;7.158639954716971E-4;0.5573555358475362;[PPP2R1A, TUBG1, PRKAR2B, PLK1, CDK1]
GO:0070374;positive regulation of ERK1 and ERK2 cascade;11.0;0.9326813400603323;0.8987696223598284;9.604993755081928;1178.864923326294;4.330336256014159;0.03945554807418015;0.6538825498434562;[PHB2, TNF, CTGF, PYCARD, TNFSF11, EPHB2, EPHB1, PDGFRB, PDGFRA, F2R, MIF, ADCYAP1, EPHA3, EPHA2, CSF1R, C5AR1, PDGFA, FPR2, TNFRSF11A, SLC30A10, PDGFD, PDGFC, CCR1, JUN, TGFB1, MARCO, BMP2, NOX4, NRP1, TREM2, PTPN22, CCR7, CD36, HAVCR2, IL1B, KIT, CHI3L1, XCL1, CCL13, NOD2, GNAI2, CCL8, GPNMB, CCL7, CCL5, CCL4, CCL2, CCL1, CCL19, CCL18, CD74, CCL23, CCL21, CCL20, TIE1, CD4, TEK]
GO:0030279;negative regulation of ossification;5.0;0.8436909121759173;0.712086467948879;9.377209824211215;41.83246312675316;5.500407508664414;0.0014000948940798496;0.571532107649126;[CALCA, ECM1, TWIST1, TNF, GATA1, HOXA2, MEN1, CCR1, MEF2C, TGFB1, IGFBP5, TMEM64, AXIN2, GREM1, ID1]
GO:0071901;negative regulation of protein serine/threonine kinase activity;11.0;0.7369933605727446;0.8009256326160346;9.385578073881732;1262.8536775520981;4.8942717050940985;0.0422665760931464;0.6827222349350845;[CDKN1A, TNFAIP3, PTPN22, PYCARD, HHEX, DUSP10, PPP2R1A, NUP62, AKT1, MEN1, DUSP2, MYOCD, DUSP1, PAQR3, PRKCD, IRAK3, SIRT1, DUSP6, SFRP2, PRKAR1B, IL1B, PRKAR2B, SFN, LYN, CDKN2C, CAV1, PLK1, NR2F2, PTPN6, PKIG]
GO:0051754;meiotic sister chromatid cohesion, centromeric;7.0;1.0;0.8509193652572005;9.628524252492122;116.99733732322595;8.16763571524637;0.003915795589440837;0.7686126355688037;[PPP2R1A, BUB1B, BUB1]
GO:0019932;second-messenger-mediated signaling;6.0;0.6547035408479693;0.6504720830141292;8.316337863525954;26.42836680105094;4.103750360508977;8.845336528452411E-4;0.5329862968704817;[CALML4, SLC8A1, EDNRB, PPP2R1A, CCRL2, TNFSF11, PTGDR, LHCGR, ATP1B1, ADCYAP1, ADCY9, PRKAR1B, BTK, AGTR1, CALCA, CALCRL, FPR1, ITPR3, FPR2, ADRB2, PRKAR2B, PLCG1, CCR10, CCR1, ABCA1, VCAM1, AZU1, SELE, SELP, LAT, MCTP1, LRRK2, CETN3, ADM, GRM5, CCR9, CCR7, CCR6, CD36, CCR5, CCR2, PTGIR, EDN1, AVPR1A, LAT2, MC3R, NDUFS4, CX3CR1, CAMK2D, PTGER2, CXCR5, CXCR4, CXCR6, GNAI2, PLN, CXCR1, CXCR2, DMD, CCL20, TSHR, FKBP1B, RAMP1, LGR4]
GO:0010020;chloroplast fission;6.0;1.0;0.8231203125901445;9.628524252492122;42.36455142891426;8.67846133901236;0.0014179034107047993;0.7669372290569613;[DNM2]
GO:0007094;mitotic spindle assembly checkpoint;13.0;1.0;0.9625549647676366;9.628524252492122;1801.8011146821202;6.781341354126479;0.060304661792685066;0.8093530769822879;[PLK1, BUB1B, CENPF, BUB1, MAD1L1, MAD2L1]
GO:0007093;mitotic cell cycle checkpoint;7.0;0.7140352122741334;0.7079369713942671;9.0094850440859;132.2042645947957;5.142344639450834;0.0044247577598742595;0.6138991092621975;[TOP2A, ZWILCH, BUB1B, BRCA1, KNTC1, TOPBP1, MSH6, MSH2, MAD1L1, BLM, AURKB, NAE1, BUB1, FANCI, TGFB1, PLK2, PLK1, DONSON, CDC6, ZWINT, WEE1, CENPF, CDK1, MAD2L1, BCL2L1]
GO:0060762;regulation of branching involved in mammary gland duct morphogenesis;6.0;0.8933024483968273;0.7697715367885581;9.446202695698167;93.99544391330774;8.16763571524637;0.0031459429173709623;0.7408135829017477;[TGFB1, PHB2]
GO:0014067;negative regulation of phosphatidylinositol 3-kinase signaling;8.0;1.0;0.875;9.628524252492122;238.79440420981607;7.292166977892469;0.00799223380789131;0.747921758369865;[TSC2, TWIST1, KLF4]
GO:0014065;phosphatidylinositol 3-kinase signaling;8.0;1.0;0.875;9.628524252492122;26.42836680105094;6.343086423195323;8.845336528452411E-4;0.6993857346658935;[EDN1, GATA3, AKT1]
GO:1903800;positive regulation of production of miRNAs involved in gene silencing by miRNA;10.0;0.8933024483968273;0.861892236059334;9.566003895510788;702.6387462348895;7.697632086000634;0.023516686502664728;0.8088982747154926;[TGFB1, MAP2K2, LIN28A]
GO:0085029;extracellular matrix assembly;5.0;0.7980440201809971;0.6892630219514189;9.176539128749065;38.15502461274271;6.7325511899570465;0.0012770143364957127;0.6345439928109722;[MFAP4, EFEMP2, TGFB1, LOX, IHH, MYH11, EMILIN1, LOXL1]
GO:0042532;negative regulation of tyrosine phosphorylation of STAT protein;11.0;1.0;0.9324289523296623;9.628524252492122;1231.6194323740242;7.379178354882098;0.041221194016031935;0.8098004765652196;[PPP2R1A, CAV1]
GO:0060644;mammary gland epithelial cell differentiation;5.0;0.8259837884571596;0.7032329060895001;9.117698628726131;24.20171999872632;6.943860283624253;8.100097882234571E-4;0.6453503496879909;[CEBPB, LBH, AKT1, HOXA5]
GO:1990253;cellular response to leucine starvation;8.0;1.0;0.875;9.628524252492122;117.0011271539623;7.474488534686424;0.003915922431664957;0.7572456912631272;[SESN3, RRAGD]
GO:0030307;positive regulation of cell growth;6.0;0.6954798709641801;0.6708602480722345;8.712233520617966;80.64681300048527;4.733648510761223;0.0026991762537066665;0.5651993175676412;[CYFIP1, NRP1, CPNE5, CXCL16, RPS6KA1, AKT1, EDN1, AVPR1A, SFRP2, MAP1B, S100A8, HBEGF, TAF9, PAK1, SFN, TGFB2, SYT2, FN1, CXCL12]
GO:0001666;response to hypoxia;5.0;0.811012628672052;0.6957473261969462;9.117698628726131;21.16160540946;4.1860866471696125;7.082598888462125E-4;0.5043176776701113;[MPL, PHB2, SLC8A1, LOXL2, AQP1, EDNRA, PLAU, MYB, AKT1, POSTN, PRKCE, ACTN4, ATP1B1, CLDN3, ABCB4, PSEN2, TWIST1, DPP4, CCNB1, HMOX1, EGR1, TGFB2, TGFB1, VCAM1, CAV1, NR4A2, BMP2, CXCL12, NOX4, CD24, ALAS2, SUV39H1, ADM, ALAD, MYOCD, ADSL, EDN1, KCND2, MMP2, AGTRAP, SIRT1, CBFA2T3, TGFBR3, CCNA2, IL1B, LTA, TLR2, CXCR4, KCNA5, PTGS2, THBS1, ASCL2, CST3, PAK1, E2F1, PML, FABP1, TEK]
GO:0007406;negative regulation of neuroblast proliferation;8.0;0.8933024483968273;0.8216512241984136;9.5544162803384;502.0817198454759;8.390779266560578;0.016804223319016428;0.8041048419030481;[TGFB1, CTNNA1]
GO:0032967;positive regulation of collagen biosynthetic process;6.0;1.0;0.8231203125901445;9.628524252492122;105.22247330055487;6.558197802812269;0.003521701487291661;0.6585068532133508;[PDGFRB, TGFB1, MYB, F2R, IHH, ENG, CTGF]
GO:0031999;negative regulation of fatty acid beta-oxidation;9.0;0.9326813400603323;0.8625812952104552;9.592156608321247;724.8195482541148;8.16763571524637;0.024259057984822387;0.8139338954918922;[CNR1, AKT1]
GO:0051000;positive regulation of nitric-oxide synthase activity;7.0;1.0;0.8509193652572005;9.628524252492122;123.23454311126406;6.832634648514029;0.0041245492540456985;0.7003406189322132;[FCER2, GCH1, AKT1]
GO:0097368;establishment of Sertoli cell barrier;6.0;1.0;0.8231203125901445;9.628524252492122;53.96940310801916;8.16763571524637;0.0018063073527159906;0.7408135829017477;[ARID4A, FLNA, ARID4B]
GO:0030308;negative regulation of cell growth;6.0;0.6913464685778243;0.6687935468790567;8.673012807464685;80.89021177018715;4.623782033182691;0.0027073225914839173;0.5595807407949613;[CDA, NRP1, SEMA5B, CDKN1A, ARHGAP4, TCHP, PPP2R1A, HNF4A, TNR, SEMA6A, DCC, SIRT1, GREM1, PSRC1, SFRP2, NDUFS3, FBP1, PAK1, FRZB, SPP1, TGFB2, TGFB1, CDKN2C, SEMA4B, INHBA, PML, BCL6, SIPA1]
GO:0048642;negative regulation of skeletal muscle tissue development;8.0;0.7866048967936545;0.7683024483968273;9.310070521373587;215.71554513694034;7.212124270218933;0.007219805164346847;0.7438283705770736;[MYOCD, TGFB1, TWIST1, EPHB1]
GO:0010936;negative regulation of macrophage cytokine production;8.0;1.0;0.875;9.628524252492122;311.05347994333346;8.16763571524637;0.010410680043746014;0.7926932703116032;[TGFB2, TGFB1, IRAK3]
GO:0032287;peripheral nervous system myelin maintenance;6.0;1.0;0.8231203125901445;9.628524252492122;21.34652774794371;7.8311634786251565;7.144490730959624E-4;0.7236063770733796;[FA2H, AKT1]
GO:0050714;positive regulation of protein secretion;8.0;0.6467165523344657;0.6983582761672329;8.730582659286164;381.48337166918856;4.304802954008995;0.01276790513702299;0.5951478232618299;[TNF, PYCARD, CLEC5A, SOX4, WLS, POSTN, PRKCE, F2R, GOLPH3L, MIF, ADAM9, CFTR, BLK, CD274, CSF1R, TWIST1, GATA3, NLRP3, CD14, MYH10, TGFB2, TGFB1, FZD5, IL6, ACHE, ORM1, LRRK2, PTPN22, IFIH1, FFAR2, CD34, HAVCR2, IL10, CHUK, SYK, DDX58, IL17RB, MMP12, TLR1, FGR, IL1B, IGHD, TLR8, TLR4, TLR2, NOD2, CD58, CCL19, NR1H2, MAPK14, CD2, NLRP12, CD244, IL17A]
GO:0019886;antigen processing and presentation of exogenous peptide antigen via MHC class II;5.0;1.0;0.7902410118609202;9.628524252492122;42.20009821028515;5.192106149009898;0.0014123993094755708;0.5557655617789146;[KIF11, IFI30, CTSS, HLA-DOA, HLA-DOB, AP2M1, HLA-DPA1, LAG3, FCER1G, DNM2, KIF2C, HLA-DQB1, HLA-DMA, HLA-DMB, RACGAP1, HLA-DQA2, HLA-DQA1, CD74, HLA-DRB4, CENPE, KIF18A, KIF26A, HLA-DPB1, HLA-DRA, FCGR2B, HLA-DRB1]
GO:2001046;positive regulation of integrin-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;186.95064880168647;7.9853141584524145;0.006257069970731893;0.7592887026755414;[FLNA]
GO:0033138;positive regulation of peptidyl-serine phosphorylation;10.0;0.9326813400603323;0.8815816818910864;9.59573442966913;778.6672313762616;5.152100814396198;0.026061291479152104;0.6787196871063318;[IFNA5, IFNA4, IFNA7, IFNA2, IFNA8, TNF, TCL1A, AKT1, IFNA14, IFNA16, MIF, SFRP2, IFNG, IFNA10, PTGS2, PAK1, NTF3, IFNA21, SNCA, TGFB1, CAV1, LIF, IL6, CAMK1]
GO:0042789;mRNA transcription by RNA polymerase II;11.0;1.0;0.9324289523296623;9.628524252492122;1288.3918881325048;6.832634648514029;0.043121317018375266;0.781850206004675;[C5AR1, FLNA]
GO:1902042;negative regulation of extrinsic apoptotic signaling pathway via death domain receptors;10.0;0.9326813400603323;0.8815816818910864;9.589303539338841;425.73912115989816;6.193554689224359;0.014249105244888325;0.731979686697602;[SERPINE1, HMGB2, TNFAIP3, FASLG, BRCA1, HMOX1, DAPK1, TNFRSF10B, SFRP2, BCL2L1]
GO:0016239;positive regulation of macroautophagy;8.0;0.7671156992804218;0.7585578496402109;9.242861771680136;266.06548500403863;5.666199763507158;0.008904972339694651;0.6647697194109919;[ADRB2, SESN3, HMOX1, TSC2, SIRT1, DCN]
GO:0042307;positive regulation of protein import into nucleus;9.0;0.9326813400603323;0.8625812952104552;9.592156608321247;778.7460608588023;6.063501560976162;0.02606392983099081;0.706328376990269;[LRRK2, PTGS2, CDH1, ECT2, TGFB1, JUP, PRKCD, MAPK14, IFNG, CDK1]
GO:0060751;branch elongation involved in mammary gland duct branching;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;21.218694376440094;9.777073627680469;7.101706051943016E-4;0.8231203125901445;[TGFB1]
GO:1905313;transforming growth factor beta receptor signaling pathway involved in heart development;9.0;0.9326813400603323;0.8625812952104552;9.541512875502493;60.43149861880159;9.777073627680469;0.0020225878739534935;0.896240625180289;[TGFB1]
GO:0000902;cell morphogenesis;4.0;0.6260725219892441;0.563036260994622;7.923776160253697;43.26261951924051;4.420487353008457;0.0014479609414792109;0.47606392880653703;[CYFIP1, COL12A1, IHH, SPINT2, ANTXR1, CLU, CDH5, C1GALT1C1, CDH3, POF1B, CDH1, MEF2C, ACTN1, COL23A1, CLDN3, EPHA2, SLC1A3, EPB41L5, NCKAP1L, ECT2, ST14, TGFB2, BCL11B, VDR, FN1, BCL6, ID1, NOX4, NRP1, COL14A1, ITGB3, LAMC1, ITGB7, ITGA4, STRADB, GP1BA, GREM1, PALLD, COL6A2, CDH11, COL6A1, COL6A3, CDH17, YAP1, PDPN, SLITRK6, FLNA, LAMB1, MAPK14, GRHL2, TEK]
GO:0008630;intrinsic apoptotic signaling pathway in response to DNA damage;7.0;0.9326813400603323;0.8172600352873667;9.55953138100517;84.23129647150353;5.54296712308321;0.002819145689655962;0.6343869617060081;[CDKN1A, BCL2A1, BRCA1, BRCA2, TNF, PYCARD, E2F1, HMOX1, SFN, MLH1, TNFRSF1B, SIRT1, PML, MSH6, MSH2, BCL3, EPHA2, BCL2L1]
GO:0021943;formation of radial glial scaffolds;6.0;1.0;0.8231203125901445;9.628524252492122;47.452274261266446;8.390779266560578;0.0015881849152503491;0.7522251544931926;[FLNA]
GO:0046902;regulation of mitochondrial membrane permeability;6.0;0.7436939687323844;0.6949672969563367;9.253830803050711;50.91783544047448;5.572381008289503;0.0017041741291158703;0.6080921364962873;[TP53BP2, E2F1, SFN, YWHAH, TFDP1, BCL2L1]
GO:0090190;positive regulation of branching involved in ureteric bud morphogenesis;8.0;1.0;0.875;9.628524252492122;298.04283299406984;6.832634648514029;0.009975225399176214;0.7244212536750128;[GREM1, TGFB1, HOXB7, LGR4, PAX2]
GO:0097011;cellular response to granulocyte macrophage colony-stimulating factor stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;7.57984905034425;0.0027327542132076126;0.710754145523778;[CD4, AKT1]
GO:0016242;negative regulation of macroautophagy;8.0;0.7866048967936545;0.7683024483968273;9.283683766200392;266.4734130419696;6.343086423195323;0.0089186253240128;0.6993857346658935;[LRRK2, AKT1, HMOX1, TSC2]
GO:0035307;positive regulation of protein dephosphorylation;9.0;0.811012628672052;0.801746939516315;9.464221201200845;660.9024749708963;6.063501560976162;0.022119811063664396;0.706328376990269;[PPP1R15A, PDGFRB, TGFB1, PPP1R12A, FCRL3, PRKCD, LILRB2, DLC1]
GO:0070317;negative regulation of G0 to G1 transition;7.0;1.0;0.8509193652572005;9.628524252492122;83.03241800612349;6.139487467954083;0.002779020306340262;0.6648930398837374;[EHMT2, BRCA1, BMI1, UXT, CHEK1, RBBP8, E2F1, RRM2, RAD51, TFDP1, EZH2]
GO:0071407;cellular response to organic cyclic compound;5.0;0.5310727365277519;0.5557773801247963;7.0299582842316;63.0333181336412;3.907776714546695;0.0021096684316296343;0.4900848947730398;[IL1RN, AQP9, IFIT1, AQP1, LGALS1, AKT1, CYP1B1, MEF2C, KCNQ1, CFTR, ABCB4, ABCA1, EGR1, JUP, COL1A1, ID1, NOX4, EZH2, GABRB1, BRCA1, IFIH1, IL10, EDN1, ANXA1, ARG1, IL1B, PTAFR, PTGS2, GNAI1, CTNNA1, SPP1, P2RY13, POU4F1, TNC, TNF, SLC8A1, CDH1, RUVBL2, IGFBP5, ADCYAP1, BLM, FECH, FOXO1, CCNB1, OSBPL7, TGFB1, CAV1, INHBA, NFKB1, NFKBIA, BMP2, KIF18A, NR4A3, ALPL, SLC26A3, LRRK2, PDE4B, DDX58, DNM2, CCNA2, COLEC12, CEBPB, NOD2, P2RY6, CCL5, CCL2, SNCA, KLF4, RAD51, KLF5]
GO:0010389;regulation of G2/M transition of mitotic cell cycle;8.0;0.7369933605727446;0.7434966802863723;8.986670366319727;58.92720908338202;4.74012102526684;0.001972240656975688;0.6174100096703167;[PPP2R1A, CDC25A, MSH6, BLM, CCNB1, PRKAR2B, NAE1, FANCI, PLK1, CDC6, CDK1, BRCA1, TOPBP1, TUBG1, RAD51C, DTL, SMARCD3, AURKB, DONSON, CENPF]
GO:0071526;semaphorin-plexin signaling pathway;6.0;0.811012628672052;0.7286266269261705;9.089527751759436;26.50247477320489;6.166155715036245;8.87013979980389E-4;0.6384578026126634;[NRP1, SEMA5B, NRP2, SEMA6A, PLXND1, SEMA4B, ARHGDIA, FLNA, PLXNB2]
GO:0043406;positive regulation of MAP kinase activity;12.0;0.7043150770688792;0.8002778511245842;9.369013057007038;2605.6877929993507;4.201124524534153;0.08721002546492271;0.6629660161470909;[, IL1RN, TNF, PROK2, TNFSF11, PDGFRB, MAP2K2, F2R, MIF, ADAM9, C5AR1, FPR1, TGFA, PDGFA, TNFRSF11A, IQGAP3, PDGFD, PDGFC, S100A12, ELANE, DRD4, MAP2K6, TGFB1, FZD5, FZD8, GH1, BMP2, CDK1, NOX4, CSPG4, CD24, EZH2, CD40, LRRK2, GHR, MAP4K1, EDN1, SYK, DUSP6, MDFIC, IL1B, KIT, PDE5A, TLR6, TLR4, CXCR4, NOD2, THBS1, PAK1, NTF3, CSK, CCL19, CD74, EGF, MAPK14, CD40LG, PKN1]
GO:0031065;positive regulation of histone deacetylation;10.0;0.8933024483968273;0.861892236059334;9.571365838652174;1219.9035963218012;6.8867018697843045;0.04082907552693193;0.7674272657460779;[TGFB1, LRRK2, BCL6]
GO:0008286;insulin receptor signaling pathway;8.0;0.8653626801206646;0.8076813400603323;9.34084218004034;31.002284443533863;5.346256828837156;0.0010376185600805164;0.6484078228531001;[AKT1, GAB1, FOXO1, CAV2, SORBS1]
GO:0008285;negative regulation of cell proliferation;5.0;0.5619039856592722;0.5711930046905564;7.31175452450612;43.614270733588945;3.2818080717434612;0.0014597303911579066;0.4580728292695636;[SPARC, SPINT2, PHB2, CYP1B1, EPHB1, SOX7, SOX4, MEF2C, EREG, SFRP4, SFRP2, SPINT1, BTK, GATA3, GATA1, INPP5D, HMOX1, SFN, LYN, JUN, BCL11B, FZD5, LIF, CDC6, NR2F2, NOX4, SNAI2, CDKN1A, TNFRSF13B, TGFB1I1, ADM, PRL, PTPRK, BRCA2, LRRC32, HNF4A, TIMP2, CTLA4, CD33, HAVCR2, IL10, DUSP1, ARG1, PAWR, PDCD1LG2, CBFA2T3, NME1, CEACAM1, IL1B, RARA, TLR2, PTGS2, ASCL2, PAK1, GPNMB, FRZB, PDPN, CTNNA1, CCL23, CDKN2C, LILRB1, LILRB2, PODN, SULF1, FAP, FABP7, DLC1, PKN1, CD86, CD80, SIRPG, IHH, TNF, CDH5, DACH1, MEN1, IGFBP5, IGFBP3, F2R, TPM1, TSC2, ADCYAP1, HGS, MAD1L1, CD274, CSF1R, CUL5, FBLN1, CNN1, NACC2, IGFBP7, TGFB2, TGFB1, RARRES3, CAV2, VDR, CAV1, HMGA1, DHCR24, INHBA, IL6, BMP2, BCL6, OGN, TNFAIP3, CXCL1, DUSP10, ADAMTS1, NUP62, PTGIR, MYOCD, AXIN2, TGFBR3, GREM1, TFDP1, IFNG, ASPH, LTA, XCL1, PDE5A, CEBPB, DLL1, THBS1, CCL8, E2F1, CCL2, ZNF503, CSK, E2F7, KLF4, PML, MEIS1, DNAJA3, PMP22, CD9, PTPN6, MNDA, FCGR2B]
GO:1902176;negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway;10.0;0.8653626801206646;0.8479223519212526;9.600353375525426;999.3623287810346;6.781341354126479;0.033447757776597226;0.7620391240755716;[SIRT1, VNN1, AKT1]
GO:0007195;adenylate cyclase-inhibiting dopamine receptor signaling pathway;9.0;1.0;0.896240625180289;9.628524252492122;58.23053162461359;7.474488534686424;0.0019489234893997154;0.7784863164434164;[FLNA, DRD4]
GO:0008284;positive regulation of cell proliferation;5.0;0.5587538620495764;0.5696179428857084;7.270369308343265;43.45254999490143;2.9881018846882994;0.0014543177435732513;0.44305268120482816;[PID1, TFRC, MYB, HOXA3, AKT1, PROK2, MEF2C, CLDN7, AGTR1, PRKCQ, ATF3, HHLA2, PDGFA, IQGAP3, GATA1, PDGFD, PDGFC, HMOX1, NCKAP1L, PLCG1, ELANE, LYN, JUN, FN1, CDC6, NOX1, CDKN1A, ADM, HOXC10, TIMP1, HLA-DPA1, HAVCR2, ANXA1, ARG1, FCRL3, SIRT1, F3, PAX2, MMP12, RARA, HBEGF, PTAFR, KCNA5, PTGS2, HLA-DMB, EPCAM, NTF3, FLNA, CCL19, IL12RB1, IL12RB2, LRG1, HLA-DPB1, CHRM1, TNC, TNF, CTGF, FGF5, PYCARD, CDH3, IGFBP5, F2R, MSH6, ADCYAP1, CD274, CSF1R, BLM, CALCRL, TNFRSF11A, CORO1A, NACC2, CXCL10, CXCL12, PTPRC, BCL6, CDK1, HPSE, BCL2L1, ITGB3, FASLG, CYR61, TNFSF13B, LBH, ITGA4, XCL1, BIRC5, CX3CR1, SMARCD3, LRP2, NOD2, CCL5, E2F1, CTHRC1, PRRX1, PML, KLF5, PRC1, DNAJA3, PTPN6, AQP1, CDC20, TCL1A, EDNRB, SKP2, TNS3, ICOSLG, SOX4, FLT3LG, MIF, RUNX2, EREG, BTC, SFRP2, IL23A, TGFA, TWIST1, CD1D, PKHD1, EGR1, EGR3, TNFSF12, TNFSF13, LIF, PTK2, BST1, ID1, CD28, CD24, CD320, NRP1, NRP2, ECM1, CD40, CTSZ, PRL, CD3E, BMI1, ESM1, RAC2, CTSH, CCR2, IL10, EDN1, SYK, RHOG, PDCD1LG2, AVPR1A, NME1, HCK, CEACAM6, IL1B, KIT, YAP1, GNAI2, CST3, PURA, PAK1, CXCR2, CD74, CDX2, LILRB2, KITLG, CD40LG, CD86, CD80, SIRPG, MPL, IHH, IL6R, PDGFRB, GHSR, PDGFRA, CCNE2, CCNE1, PRTN3, CARD11, C5AR1, HTRA1, LTBP3, DPP4, CCNB2, CCNB1, TGFB2, TGFB1, VCAM1, CAV2, NR4A1, IL6, BMP2, LIN28A, NR4A3, HMGB2, TNFAIP3, LAMC2, LAMC1, CXCL5, MYOCD, MMP2, GLP2R, MMP9, TGFBR3, CCNA2, GREM1, ZAP70, IFNG, NDUFS4, LTA, LTF, DLL1, THBS1, S1PR3, EGF, LAMB1, MAPK14, MEIS2, TSHR, CD4, CD6, TEK]
GO:0002062;chondrocyte differentiation;4.0;0.8933024483968273;0.6966512241984136;9.446202695698167;21.066225782797595;6.039404009397101;7.050676185779127E-4;0.5588554019015759;[MEF2C, TGFB1, IHH, AXIN2, MAPK14, RUNX2, BMP2, TGFBI]
GO:0002184;cytoplasmic translational termination;7.0;1.0;0.8509193652572005;9.628524252492122;40.68669918132259;8.67846133901236;0.0013617472059468932;0.7947362817240173;[GSPT1]
GO:1901525;negative regulation of mitophagy;9.0;0.9326813400603323;0.8625812952104552;9.592156608321247;765.9069832582293;7.9853141584524145;0.0256342174581193;0.8046099625986299;[TSC2]
GO:0045944;positive regulation of transcription by RNA polymerase II;11.0;0.5461734764479651;0.7055156905536448;8.363590748376499;1463.8556817380634;2.718315475161805;0.048993932283191266;0.5714437321440341;[EHF, PID1, SPI1, SERPINE1, SPIB, MYB, HOXA3, AKT1, HOXA2, HOXA7, HOXA5, MEF2A, MEF2C, HOXB9, HOXB4, HOXB3, HOXB2, MAML3, HOXB7, ATF3, HOXB5, GATA3, GATA1, NKX2-3, JUN, JAG1, JUP, FZD5, FZD8, HOXC10, PAX5, FOS, SIRT1, PAX2, MMP12, RARA, ENG, NR1I2, EPCAM, STAT4, NR1H2, ATAD2, GTF2H1, POU4F1, PSMC6, PSMC2, FOSB, PF4, CCNT2, PLXND1, TNF, RUVBL2, MEN1, ADCYAP1, FOXO1, NFKB1, CXCL10, COPS5, MAFF, BCL3, CIITA, CYR61, HHEX, PPP1R12A, CHUK, PEG3, TFDP1, CEBPB, CEBPE, NOD2, ABLIM3, E2F1, E2F2, E2F5, E2F7, PRRX1, KLF4, PML, KLF1, KLF5, POU2AF1, CCNH, RPS6KA1, TNFSF11, DPF3, SOX4, SLC11A1, EBF1, FLT3LG, HNF1B, RUNX2, SFRP2, IL23A, BEX1, TWIST1, NHLH2, EGR1, EGR2, EGR3, BCL11B, LIF, CD28, TOP2A, CD40, HNF4G, PRL, BRCA1, CD3D, HNF4A, IL10, EDN1, RGMA, IL1B, TFEC, TLR4, TLR2, YAP1, SATB2, CDX1, LILRB1, GRHL2, CAMK1, FOXA3, IL17A, FOXA2, IHH, ARID4A, ARID4B, HOXA10, ADRB2, NLRP3, TGFB2, TGFB1, VDR, HMGA1, INHBA, NR4A2, NFKBIA, NR4A1, IL6, BMP2, NR4A3, TCF4, HMGB2, SLC40A1, ARHGEF10L, MYOCD, DDX58, CKAP2, ETV1, DCN, GREM1, ELF3, IRF7, TAF9, DLL1, LUM, MAPK14, MEIS2, MEIS1, RBMX]
GO:0043525;positive regulation of neuron apoptotic process;8.0;0.8436909121759173;0.7968454560879586;9.392135474427892;179.36331192335928;5.885253329569843;0.0060031286335741505;0.6759721289664703;[CTSZ, FASLG, MYB, JUN, TGFB2, CDC34, IL1B, UBE2M]
GO:1902856;negative regulation of non-motile cilium assembly;10.0;1.0;0.9152410118609203;9.628524252492122;402.0466438491823;8.67846133901236;0.013456139351143913;0.8590579283277371;[DNM2]
GO:0001893;maternal placenta development;4.0;1.0;0.75;9.628524252492122;43.252245699280884;7.379178354882098;0.001447613739060994;0.6273715242355574;[AKT1, NR2F2]
GO:0048538;thymus development;5.0;1.0;0.7902410118609202;9.628524252492122;35.890675140737365;6.039404009397101;0.0012012285974499148;0.5990964137624962;[SLC46A2, GATA3, CCNB2, HOXA3, BCL11B, MAD1L1]
GO:0043524;negative regulation of neuron apoptotic process;8.0;0.7866048967936545;0.7683024483968273;9.245532000236016;179.62959498689688;4.864418741944418;0.006012040888071555;0.6237666006816429;[NRP1, CHL1, MEF2C, F2R, MSH2, NAIP, CEBPB, LRP1, C5AR1, SLC30A10, CORO1A, NTF3, CCL2, HMOX1, FYN, SNCA, JUN, WFS1, GABRA5, POU4F1, NR4A2, NR4A3, BCL2L1]
GO:0006417;regulation of translation;7.0;0.5221699919663294;0.6120043612403652;8.01908634005802;212.8215771898108;3.9901762463137618;0.007122946661558481;0.554977164055858;[CYFIP1, MAGOH, RPS6KA1, AKT1, SOX4, DAPK1, UPF3B, CD28, BANK1, RARA, PTAFR, PURA, PPP1CA, FMR1, TNF, IGFBP5, EIF2S1, IL6, LIN28A, CNOT3, BCL3, GRM5, PPP1R15A, THBS1, CCL5, EIF4H, EIF3K, EIF3H, EIF3E, EIF3D]
GO:0048661;positive regulation of smooth muscle cell proliferation;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;63.45804869205661;5.433268205826786;0.002123883781187112;0.6009779013089371;[TNF, MYB, AKT1, SKP2, IL6R, PDGFRB, IL10, EDN1, IGFBP5, MMP2, MMP9, EREG, HBEGF, CALCRL, PTAFR, PTGS2, THBS1, GNAI2, PAK1, CCL5, PDGFD, HMOX1, ELANE, JUN, IL6, NR4A3, NOX1]
GO:0010918;positive regulation of mitochondrial membrane potential;5.0;1.0;0.7902410118609202;9.628524252492122;24.658349685322438;7.57984905034425;8.252927728937918E-4;0.6778748447945537;[TCL1A, AKT1]
GO:0051146;striated muscle cell differentiation;5.0;0.7436939687323844;0.6620879962271125;8.781226392104918;21.75937296335754;5.825829909099042;7.282666309192915E-4;0.5881742243410422;[POPDC3, AKT1, MEF2C, MYOCD, CHUK, IGFBP5, SORT1, AVPR1A, MAPK14, BMP2, RARA, NOX4, SIK1]
GO:0070584;mitochondrion morphogenesis;5.0;1.0;0.7902410118609202;9.628524252492122;64.70445744698846;6.781341354126479;0.002165599960519628;0.6370391240755715;[PID1, NDUFS6, MYH14, SSBP1, BCL2L1]
GO:0071677;positive regulation of mononuclear cell migration;9.0;0.8933024483968273;0.8428918493787028;9.533214072687796;295.2864367703214;6.686031174322154;0.009882971298162901;0.7381645703673706;[CCR1, TGFB1, SERPINE1, FPR2, PLA2G7, TNF, LGALS3, CXCL10, CXCL12, CCL5, PDGFD, CCL1, S100A14, CCR2]
GO:0001649;osteoblast differentiation;4.0;1.0;0.75;9.628524252492122;21.066225782797595;5.171903441692378;7.050676185779127E-4;0.5144913825262545;[TNC, IHH, FHL2, CYR61, FBL, AKT1, MEF2C, TPM4, IGFBP5, IGFBP3, RUNX2, VCAN, COL6A1, EPHA2, HSD17B4, TWIST1, GPNMB, FIGNL1, SPP1, HSPE1, COL1A1, BMP2, PSMC2, ALPL, SNAI2, RBMX, LGR4]
GO:0032147;activation of protein kinase activity;11.0;0.6799073451904818;0.7723826249249031;9.164951513576677;1096.8683293671154;4.034070439870987;0.03671119586651001;0.6387315022281249;[, TNF, AKT1, PROK2, TNFSF11, PRKACB, MAP2K2, SLC11A1, F2R, PRKCD, PRKAR1B, ADAM9, CALCA, C5AR1, FPR1, TGFA, ADRB2, IQGAP3, PRKAR2B, PDGFC, NCKAP1L, ECT2, DRD4, MAP2K6, TGFB2, TNFRSF10B, BMP2, CDK1, CSPG4, LRRK2, ITGB3, GHR, MAP4K1, SYK, STRADB, DUSP6, GREM1, MDFIC, IL1B, KIT, CHI3L1, TLR6, TLR4, CXCR4, NOD2, THBS1, PAK1, NTF3, CCL19, CD74, EGF, MAPK14, CD40LG, PKN1]
GO:0071312;cellular response to alkaloid;6.0;0.7866048967936545;0.7164227609869718;9.245532000236016;164.36700762083373;6.280566066213989;0.005501215824366272;0.6443087532925187;[BLM, ABCB4, SLC8A1, CCNA2, RAD51, BCL2L1]
GO:0032700;negative regulation of interleukin-17 production;6.0;0.8653626801206646;0.7558016526504768;9.427853557029971;65.25422870398782;7.292166977892469;0.002184000309729388;0.6960420709600095;[TGFB1, IFNG, NCKAP1L, TLR4]
GO:0034329;cell junction assembly;4.0;0.7140352122741334;0.6070176061370667;8.529911963824013;35.00514165935835;4.7018998124466425;0.0011715905887565515;0.49045537506922354;[ITGB4, LAMC2, PTPRK, LAMC1, F11R, ARHGAP6, CDH5, CDH3, POF1B, CDH1, TNS1, ACTN1, LSR, ACTN4, CLDN3, CDH11, PKP3, TLN1, CDH17, VCL, CD151, LAMA3, THY1, GJC1, EPB41L3, CTNNA1, FLNA, ECT2, VASP, JUP, LAMB3, FN1, SORBS1, GRHL2, GJB2, DLC1, CD9]
GO:0050731;positive regulation of peptidyl-tyrosine phosphorylation;10.0;0.7866048967936545;0.8085434602577476;9.446202695698167;779.3603785568229;4.60092389510664;0.02608449049149353;0.6505324738215158;[NRP1, CD40, CD80, ITGB3, IFNA2, TREM2, CD3E, GHR, GRM5, CD36, IL6R, SYK, MIF, EREG, GREM1, IFNG, BANK1, IL23A, KIT, HBEGF, CSF1R, TGFA, GATA1, CCL5, NTF3, STAP1, FYN, LYN, CD74, TGFB1, ACE, EGF, LIF, GH1, CD4, IL6, CSPG4, CD24]
GO:0032148;activation of protein kinase B activity;12.0;1.0;0.9481203125901445;9.628524252492122;1099.1709144601095;6.311337724880743;0.03678826131738048;0.770882417347765;[NTF3, AKT1]
GO:0035655;interleukin-18-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;7.8311634786251565;0.00101047745553359;0.7514054297404357;[IL18RAP, ALOX5, AKT1, IL18R1]
GO:0016479;negative regulation of transcription by RNA polymerase I;11.0;0.8653626801206646;0.8651102923899945;9.548481544818586;1834.662418985909;8.16763571524637;0.06140450007447906;0.8501222226412654;[FLNA, POU4F1]
GO:0016579;protein deubiquitination;9.0;0.7307253602413294;0.7616033053009538;9.151600180401813;202.59641706362558;4.174954806800768;0.0067807197541817285;0.6097480081553338;[CDC20, RUVBL1, PSMD3, SKP2, CDC25A, CFTR, PSMD14, ADRB2, GATA3, NLRP3, BARD1, NFKBIA, COPS5, CDK1, TNFAIP3, BRCA1, IFIH1, DDX58, ACTL6A, PSMA5, CCNA2, PSMA6, PSMA3, PSMA4, PSMA2, FAM105A, USP1, USP9Y, PSMC6, PSMC2, EIF3F]
GO:0043537;negative regulation of blood vessel endothelial cell migration;10.0;0.9326813400603323;0.8815816818910864;9.584072489921288;356.3539069568923;6.311337724880743;0.01192684456815238;0.7380031166185408;[MEF2C, TGFB1, JUP, KLF4, THBS1]
GO:0031295;T cell costimulation;9.0;0.9326813400603323;0.8625812952104552;9.587702257971866;354.8971974647038;5.845247994956144;0.011878089812402261;0.6951668794741764;[CD86, CD274, HHLA2, CD80, CD3E, TNFSF13B, DPP4, PAK1, KLRK1, LGALS1, GRAP2, BTLA, AKT1, CTLA4, FYN, CSK, CCL19, ICOS, ICOSLG, LYN, TNFSF14, CCL21, CAV1, PDCD1LG2, VAV1, CD40LG, LCK, CD28, PTPN6, CD24, CARD11]
GO:0031293;membrane protein intracellular domain proteolysis;7.0;0.9326813400603323;0.8172600352873667;9.533214072687796;50.748517158788495;6.8867018697843045;0.0016985071986044009;0.7031056191423581;[TGFB1, PSEN2, NFKB1]
GO:0060416;response to growth hormone;7.0;0.9326813400603323;0.8172600352873667;9.541512875502493;74.03337757263446;7.138016298065211;0.0024778305216419678;0.7159578506919597;[GHSR, IGFBP5, AKT1]
GO:0051280;negative regulation of release of sequestered calcium ion into cytosol;10.0;0.8933024483968273;0.861892236059334;9.566003895510788;673.651588659943;7.212124270218933;0.02254651242537939;0.7840693824379941;[TGFB1, FKBP1B]
GO:0009267;cellular response to starvation;6.0;0.6369964171292115;0.6416185211547503;8.460919092337061;112.76702064936369;4.807260328104469;0.0037742106974044997;0.5689638293298743;[CDKN1A, PLEKHF1, EHMT2, LRRK2, KRT20, SESN3, LAMP2, UPP1, SIRT1, RRAGD, SIK1, ATF3, SEH1L, FOXO1, GAS2L1, JUN, EIF2S1, FOXA3]
GO:0006672;ceramide metabolic process;7.0;0.7140352122741334;0.7079369713942671;9.176539128749065;101.21355503378848;5.420364800990877;0.0033875266006951925;0.628117073252615;[GAL3ST1, SGMS1, FUT3, GM2A, PPP2R1A, ITGB8, P2RX1]
GO:0043536;positive regulation of blood vessel endothelial cell migration;10.0;0.9326813400603323;0.8815816818910864;9.584072489921288;355.43002650478036;5.8067817141283475;0.011895923120858621;0.7122000987644093;[NRP1, CD40, PTGS2, THBS1, AKT1, HMOX1, PLCG1, TGFB1, ANXA1, PLK2, SIRT1]
GO:0001541;ovarian follicle development;4.0;1.0;0.75;9.628524252492122;34.608406302298;6.166155715036245;0.001158312213394382;0.5653374900225189;[CEBPB, INHBA, FANCG, ADCYAP1, KIT, CTNNA1, MMP19, BCL2L1]
GO:0009817;defense response to fungus, incompatible interaction;7.0;1.0;0.8509193652572005;9.628524252492122;143.15190279508232;9.777073627680469;0.004791165358203135;0.8509193652572005;[TGFB1]
GO:0019050;suppression by virus of host apoptotic process;11.0;0.9326813400603323;0.8987696223598284;9.597752593825367;597.6589218595425;8.67846133901236;0.02000310625652992;0.8762458687964789;[BCL2L1]
GO:0030516;regulation of axon extension;10.0;0.7866048967936545;0.8085434602577476;9.474373572664863;209.02857457674645;5.244474134527214;0.0069959982775799475;0.6834436629936306;[CYFIP1, NRP1, SEMA5B, ARHGAP4, DPYSL2, TNR, SEMA6A, DNM2, MAP1B, RAB21, PAK1, SEMA4B, FN1, CXCL12]
GO:0006306;DNA methylation;9.0;0.7436939687323844;0.7680876095464813;9.253830803050711;389.4685312710283;5.948432231191374;0.01303516124271949;0.7004437261138039;[EHMT2, FOS, EZH2]
GO:0001657;ureteric bud development;8.0;1.0;0.875;9.628524252492122;36.921511297847346;6.139487467954083;0.0012357297559360753;0.6889736746265369;[ROBO2, TGFB1, EPCAM, RARA, SDC1]
GO:0051152;positive regulation of smooth muscle cell differentiation;7.0;0.811012628672052;0.7564256795932265;9.303101852057495;145.28799013580416;7.292166977892469;0.004862658279143298;0.7238411236270654;[MYOCD, TGFB1, SMARCD3, KIT, SIRT1, ENG]
GO:0010800;positive regulation of peptidyl-threonine phosphorylation;10.0;1.0;0.9152410118609203;9.628524252492122;778.6672313762616;6.375876246018314;0.026061291479152104;0.7413036195908642;[TGFB1, EGF, PLK1, AZU1, CHI3L1]
GO:0071549;cellular response to dexamethasone stimulus;9.0;1.0;0.896240625180289;9.628524252492122;704.2721689024621;6.343086423195323;0.023571355689363423;0.7206263598461826;[TGFB1, FECH, ARG1, ABCB4, FOXO1, AQP1]
GO:0030512;negative regulation of transforming growth factor beta receptor signaling pathway;8.0;0.8933024483968273;0.8216512241984136;9.537552474286395;374.7458266990886;5.54296712308321;0.012542405570270547;0.6584675964488075;[TGFB1I1, HTRA1, PRDM16, EMILIN1, TGFB1, CAV2, CAV1, SIRT1, DNM2, TGFBR3, FBN1]
GO:0032930;positive regulation of superoxide anion generation;8.0;1.0;0.875;9.628524252492122;144.57516735605006;7.004484905440688;0.00483880074220378;0.7332096838060964;[TGFB1, ITGAM, PRKCD, ITGB2, FPR2, GNAI2, CD177]
GO:0034394;protein localization to cell surface;5.0;1.0;0.7902410118609202;9.628524252492122;29.829169826127035;6.686031174322154;9.983554695705216E-4;0.6321649570480018;[FLNA, PTPRK, VCL, CD177]
GO:1901381;positive regulation of potassium ion transmembrane transport;9.0;0.7369933605727446;0.7647373054666613;9.271849308553389;341.4877247401287;6.311337724880743;0.01142928682805268;0.7190027299379095;[KCNH2, KCNQ1, FLNA, ATP1B2, ATP1B1, DNM2]
GO:1902230;negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage;10.0;0.9326813400603323;0.8815816818910864;9.596775554177542;831.2496569477559;6.409777797693995;0.02782117794191935;0.7430373465201421;[CD74, TAF9, MIF, SIRT1, CLU, CXCL12, SFRP2, SNAI2, BCL2L1]
GO:0042176;regulation of protein catabolic process;6.0;0.5945822691631375;0.6204114471717133;8.214830917184116;56.791667214012804;3.8826707934156186;0.001900765992470805;0.5216802775280761;[PSMD3, AKT1, BARD1, PLK2, TNFSF12, PLK1, PTK2, XPO1, TIMP2, TIMP3, TIMP1, IL10, CBFA2T3, RNF144B, IL1B, CST3, FLNA, PSMC6, PSMC2, MAD2L1, FMR1, TNF, CLU, HGS, ADAM9, PSMD14, FOXO1, OSBPL7, CAV1, DAB2, CCDC22, LRRK2, TNFAIP3, ALAD, IRAK3, TNFRSF1B, IFNG, DTL, LRP1, TAF9, LRP2, FYN, SNCA, EGF, PML]
GO:0046777;protein autophosphorylation;8.0;0.7763722522362496;0.7631861261181248;9.31486669363708;180.75330000196035;4.488806596985934;0.006049650283656873;0.604557778120715;[SLA2, GRAP2, AKT1, EPHB1, PDGFRB, PDGFRA, MAP2K2, DAPK1, VRK1, MELK, BTK, SIK1, BLK, CSF1R, THY1, LYN, BMX, EIF2S1, CLK4, PTK2, CLK1, FES, ITK, LRRK2, MAP4K1, SYK, CAD, IRAK3, FGR, ZAP70, HCK, LCK, KIT, CAMK2D, AURKB, PAK1, FYN, CSK, CAMK4, TEK]
GO:0042177;negative regulation of protein catabolic process;7.0;0.7140352122741334;0.7079369713942671;9.105276108727574;231.8232476428224;5.040875179285974;0.007758915471227624;0.6087099563505541;[ALAD, TIMP2, TIMP3, TIMP1, IL10, IRAK3, TAF9, CST3, FLNA, FYN, SNCA, PML, MAD2L1]
GO:0046898;response to cycloheximide;5.0;0.9326813400603323;0.7565816818910864;9.55953138100517;150.26211428142383;8.390779266560578;0.0050291377378760905;0.7193458537639684;[KLF4, BCL2L1]
GO:0006006;glucose metabolic process;6.0;0.7090535922965819;0.6776471087384355;8.572471578242808;34.676020684410545;5.040875179285974;0.0011605752059146955;0.5809109036834981;[TNF, HK3, AKT1, PGM5, IGFBP5, NPY1R, BPGM, OAS1, FBP1, ATF3, MAPK14]
GO:0032091;negative regulation of protein binding;5.0;0.6997970393407541;0.6401395315312973;8.48339194818912;32.716075545242866;5.171903441692378;0.0010949776059428606;0.5547323943871747;[LRRK2, CTSZ, IFIT1, RUVBL2, STMN1, AKT1, IL10, ITGA4, PRKCD, AES, SLPI, ADRB2, AURKB, EPB41L5, CCL23, CAV1, EIF2S1, PPP1CA, DAB2, ID1, CAMK1]
GO:0043029;T cell homeostasis;7.0;1.0;0.8509193652572005;9.628524252492122;22.00128503895464;6.444869117505266;7.363632103827933E-4;0.6805102716434839;[TGFB1, SLC46A2, TNFSF14, CACNA1F, CORO1A, CCNB2, SIT1, NCKAP1L]
GO:0009749;response to glucose;7.0;0.8933024483968273;0.7975705894556142;9.405380701177911;32.95598622603122;4.917261223318797;0.001103007200523252;0.6023883328937558;[SLC8A1, CTGF, LGALS1, HNF4A, SOX4, MEN1, RMI1, HNF1B, PAX2, NME1, IL1B, COL6A2, THBS1, EGR1, EIF2B3, TGFB1, LIN28A, FKBP1B, NOX4]
GO:2000679;positive regulation of transcription regulatory region DNA binding;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;47.96814533750694;6.641579411751319;0.0016054506559182917;0.6627709925721352;[TGFB1, IFNG, TWIST1, GATA3, KLF4, POU4F1]
GO:0043154;negative regulation of cysteine-type endopeptidase activity involved in apoptotic process;12.0;0.8653626801206646;0.8808016526504769;9.556203590912496;734.4861809891323;5.277263957350204;0.024582591483058774;0.7179998367869053;[TNFAIP8, AQP1, RPS6KA1, AKT1, PLAUR, SERPINB9, TNFRSF1B, MMP9, PAX2, POR, SFRP2, BIRC5, NAIP, IFI6, NLRC4, PTGS2, THBS1, SFN, SNCA, TNFSF14, TNFRSF10C, TNFRSF10B, DHCR24, KLF4, FABP1, VIL1]
GO:0071732;cellular response to nitric oxide;6.0;1.0;0.8231203125901445;9.628524252492122;346.50110413771324;7.004484905440688;0.011597080124741305;0.6813299963962409;[CCNA2, FOXO1, DNM2, AQP1]
GO:0030100;regulation of endocytosis;6.0;0.5902001590945054;0.6182203921373972;8.152617732682543;44.90533409728707;4.321752512322768;0.0015029411200592913;0.5441349370523758;[FMR1, SIRPG, SERPINE1, TNF, CLU, PYCARD, LGALS3, CD177, SLC11A1, TSC2, ACTN4, SFRP4, PRTN3, EPHA3, CD151, STAP1, NCKAP1L, CD14, TGFB1, CAV1, AZU1, SELE, TF, DAB2, MCTP1, LRRK2, SIRPB1, CD36, FCER1G, SYK, DNM2, FGR, GREM1, HCK, IL1B, TLR2, NLGN1, LRP1, DLL1, RAB21, NTF3, CCL2, CSK, CCL19, SNCA, CCL21, EGF, NR1H2, LILRB1, PTX3, FCGR2B]
GO:0010975;regulation of neuron projection development;8.0;0.5673924682959377;0.6586962341479689;8.404748820870006;84.29486529122617;3.652390236786265;0.0028212732808438556;0.5617834065627654;[CYFIP1, CPNE5, CDC20, LGALS1, DPYSL2, AKT1, EPHB2, MEF2C, PAQR3, SFRP2, MAP1B, EPHA3, SDC2, GATA3, THY1, LYN, FZD1, PLK2, FN1, PTK2, ID1, EZH2, ITM2C, ROBO2, NRP1, CTSZ, ARHGAP4, RGMA, NME1, PAK1, SPP1, XK, FKBP1B, CAMK1, SCARB2, SEMA5B, PLXND1, FMR1, ARHGDIA, TNR, SEMA6A, ADCYAP1, SYT2, CXCL12, FES, PLXNB2, LRRK2, YWHAH, DCC, DNM2, SHANK3, NLGN1, LRP1, RAB21, CNR1, FYN, LINGO1, PRRX1, SEMA4B, KLF4, PMP22]
GO:0051567;histone H3-K9 methylation;11.0;0.8933024483968273;0.8790801765280758;9.56398573135455;955.3390821452521;7.474488534686424;0.03197433933004731;0.8146746435927894;[EHMT2, SUV39H1, ARID4A, ARID4B]
GO:1900182;positive regulation of protein localization to nucleus;7.0;0.8436909121759173;0.7727648213451592;9.36615998802463;74.62336946219564;5.446340287394138;0.0024975770192273523;0.6294454608352614;[LRRK2, CDH1, AKT1, CCT3, CCT2, PRKCD, IFNG, PTGS2, FYN, CCT8, CCT7, ECT2, CCT5, CCT4, TGFB1, JUP, PLK1, LIF, MAPK14, CCT6A, CDK1]
GO:0060154;cellular process regulating host cell cycle in response to virus;7.0;1.0;0.8509193652572005;9.628524252492122;44.5007138789538;8.67846133901236;0.0014893988454862319;0.7947362817240173;[BCL2L1]
GO:0060271;cilium assembly;6.0;0.8653626801206646;0.7558016526504768;9.405380701177911;137.68250629835126;4.347727998726029;0.00460810957959482;0.5454633246350222;[PKHD1, EHD3, ABLIM3, FLNA, GSN]
GO:0060395;SMAD protein signal transduction;5.0;1.0;0.7902410118609202;9.628524252492122;23.17027026302992;5.734022359845919;7.75488093814194E-4;0.5834791820027497;[JUN, TGFB2, TGFB1, INHBA, FOS, BMP2, HNF4A]
GO:0038061;NIK/NF-kappaB signaling;6.0;1.0;0.8231203125901445;9.628524252492122;26.42836680105094;6.8867018697843045;8.845336528452411E-4;0.6753065664753021;[CHUK, NFKB1, AKT1]
GO:0090261;positive regulation of inclusion body assembly;6.0;0.8933024483968273;0.7697715367885581;9.461470167828956;102.91312205862022;8.390779266560578;0.0034444095795052925;0.7522251544931926;[CDC34, CLU]
GO:0043951;negative regulation of cAMP-mediated signaling;8.0;0.7866048967936545;0.7683024483968273;9.417215158824915;239.89301649848343;6.8867018697843045;0.008029003372506139;0.7271862538851576;[CDC34, GNAI2]
GO:0000266;mitochondrial fission;5.0;1.0;0.7902410118609202;9.628524252492122;40.48578058269761;6.686031174322154;0.0013550226412659145;0.6321649570480018;[DNM2]
GO:0048298;positive regulation of isotype switching to IgA isotypes;11.0;1.0;0.9324289523296623;9.628524252492122;1407.9016349495496;8.16763571524637;0.04712120069255247;0.8501222226412654;[TGFB1, MSH2, TNFSF13, MLH1]
GO:0010629;negative regulation of gene expression;6.0;0.471430776349301;0.558835700764795;6.738152494595957;59.04642522059629;2.349334787147576;0.001976230713800692;0.44326540286011196;[SPI1, EHMT2, SLA2, AKT1, MEF2A, MEF2C, ATF3, GATA3, IQGAP3, GATA1, JUN, NR2F2, PKIG, EZH2, SIRT1, MMP12, BTAF1, FLNA, CENPF, LGR4, GMNN, CTGF, FOXO1, ZNF423, NFKB1, CIITA, LRRK2, FHL2, FASLG, HHEX, ITGB8, PEG3, BIRC5, E2F1, FYN, E2F7, PRRX1, EIF3E, UXT, HNF1B, MIF, EREG, SFRP2, IFI27, KCNQ1, NAIP, GSPT1, PCBP3, CCR1, EGR1, MSR1, ID1, CD28, SUV39H1, CTSZ, PTPRK, BRCA1, CD3E, BMI1, CD36, CD34, BANK1, IL1B, DEPDC1, SATB2, LOXL2, CCNE1, CALCA, CCNB1, VDR, CAV1, HMGA1, BMP2, MXD1, HMGB2, MYOCD, GREM1, ELF3, IRF7, FBP1, AURKB, SERPINE1, PHB2, MYB, HOXA2, HOXA7, DAPK1, HOXB4, HOXB3, SERPING1, PRDM16, ELANE, BARD1, FZD1, NDFIP2, PLK1, FZD8, UPF3B, SNAI2, CDKN1A, HAVCR2, PAWR, PAX5, PAX2, AES, RARA, GAS1, ENG, NR1I2, ASCL2, NR1H2, POU4F1, FOSB, FMR1, TNF, DACH1, MEN1, TLE4, MAP2K2, IGFBP5, AEBP1, NACC2, WFS1, LSM5, LSM3, DAB2, BCL6, CNOT3, BCL3, PTPN22, EMILIN1, CR1, RFC1, PTBP2, XCL1, CEBPB, NLRC4, RBBP8, ZNF503, KLF4, PML, KLF8, KLF5, DNAJA3, ZNF608, EDNRB, PPP2R1A, MAGOH, DPF3, SOX7, SOX4, IL1R2, RUNX2, TWIST1, BCL11A, IFNA2, XPO1, EDN1, CBFA2T3, NME1, MDFIC, PURA, CDX2, MLH1, ARID4A, CHCHD3, BASP1, TGFB2, TGFB1, CBX4, EIF2S1, NR4A2, LIN28A, NR4A3, CREBZF, H2AFX, IFNG, PFDN5, THBS1, SNCA, MEIS2, RBMX]
GO:0043161;proteasome-mediated ubiquitin-dependent protein catabolic process;9.0;0.7586651285174919;0.775573189439035;9.310070521373587;348.3589749790861;4.015022244900292;0.01165926138982685;0.6015690495021188;[, CDC20, SKP2, CDC34, PLK1, SIRT1, PSMA5, PSMA6, PSMA3, PSMA4, PSMA2, PSMC6, PSMC2, MAD2L1, BUB1B, PSMD14, CCNB1, WFS1, UBE2C, CDK1, AURKB, RNF24, PML]
GO:0007219;Notch signaling pathway;6.0;0.7763722522362496;0.7113064387082693;8.866384200445225;26.50247477320489;4.99795013456894;8.87013979980389E-4;0.5787157149004503;[TMEM100, HHEX, HNF1B, FCER2, MAML3, PSEN2, KCNA5, DLL1, PLN, GMDS, PERP, S1PR3, ZNF423, TGFB1, JAG1, KRT19, BMP2, SNAI2]
GO:0060716;labyrinthine layer blood vessel development;5.0;1.0;0.7902410118609202;9.628524252492122;85.12843743852892;6.781341354126479;0.0028491721904478507;0.6370391240755715;[FZD5, AKT1, CYR61]
GO:0010748;negative regulation of plasma membrane long-chain fatty acid transport;9.0;1.0;0.896240625180289;9.628524252492122;652.3932031735304;8.390779266560578;0.02183501339445399;0.8253454670833372;[AKT1, THBS1]
GO:0010742;macrophage derived foam cell differentiation;5.0;1.0;0.7902410118609202;9.628524252492122;21.75937296335754;7.8311634786251565;7.282666309192915E-4;0.6907270763441554;[TGFB1]
GO:0031663;lipopolysaccharide-mediated signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.50247477320489;6.343086423195323;8.87013979980389E-4;0.647506047256038;[PTAFR, LY96, PTPN22, TNF, CCL5, AKT1, CCL2, CD14, LYN, TGFB1, PRKCE, MAPK14, NFKBIA, HCK, CD6, IL1B, TLR4, TLR2]
GO:0006809;nitric oxide biosynthetic process;6.0;1.0;0.8231203125901445;9.628524252492122;241.09966064176743;7.212124270218933;0.008069388666072628;0.6919486831672181;[GCH1, AKT1, CYP1B1]
GO:0032079;positive regulation of endodeoxyribonuclease activity;9.0;1.0;0.896240625180289;9.628524252492122;975.1149925155983;8.390779266560578;0.03263622125297896;0.8253454670833372;[PRKCD, AKT1]
GO:0018105;peptidyl-serine phosphorylation;9.0;0.7369933605727446;0.7647373054666613;9.207310787415818;338.73676479787366;4.61801832846594;0.011337214674488616;0.6324062972578516;[, AKT1, STK32B, MAP2K2, PRKCE, PRKCD, VRK1, PRKCQ, CCNB1, PLK2, PLK1, CLK1, CDK1, LRRK2, MAP4K1, CHUK, SYK, SGK1, CAMK2D, AURKB, MAPK14, MAPK13, CAMK4, PKN1, CAMK1]
GO:0050921;positive regulation of chemotaxis;6.0;0.6417349323569144;0.6439877787686017;8.362857879160845;97.3409382187974;4.886724499458715;0.003257913601026301;0.5730276307483924;[NRP1, CXCL6, CXCL9, SERPINE1, CXCL1, CXCL13, CXCL3, CXCL2, CXCL5, C3AR1, RAC2, CCR7, CCR6, IL6R, CCR2, PDGFRB, EDN1, F3, IL23A, IL1B, XCL1, SUCNR1, C5AR1, FPR2, PLA2G7, THBS1, CCL7, CCL5, PDGFD, CXCR2, CCL4, NTF3, CCL1, NCKAP1L, CCL19, S100A14, CCR1, CD74, TGFB1, TNFSF14, CCL21, AZU1, PPBP, MAPK14, CXCL10, CXCL11, IL6, CXCL12, PF4]
GO:0030212;hyaluronan metabolic process;7.0;0.8933024483968273;0.7975705894556142;9.510741216835738;101.21806367924876;6.280566066213989;0.0033876775010012305;0.6721078059595746;[TGFB1, PKHD1, IL1B, AKT1]
GO:0010862;positive regulation of pathway-restricted SMAD protein phosphorylation;10.0;1.0;0.9152410118609203;9.628524252492122;1012.5567145242198;5.905872616772578;0.033889361993245395;0.7172676121338334;[TGFB2, TGFB1, INHBA, BMP2, DAB2, ENG]
GO:0018107;peptidyl-threonine phosphorylation;9.0;0.7671156992804218;0.7797984748205;9.305750860229072;337.99482745314367;5.395046993006588;0.011312382699260763;0.6721435792979885;[LRRK2, CHEK1, AKT1, PRKCD, CAD, VRK1, CAMK2D, CLK1, CDK1, PKN1, CAMK1]
GO:0030214;hyaluronan catabolic process;8.0;1.0;0.875;9.628524252492122;501.2795327383162;6.8867018697843045;0.01677737483846132;0.7271862538851576;[PKHD1, TGFB1]
GO:0061035;regulation of cartilage development;5.0;0.7043150770688792;0.6423985503953599;8.781226392104918;27.37613670804801;5.6339389012889365;9.162546586948941E-4;0.5783609092777888;[TGFB1, AXIN2, ADAMTS12, RUNX2, CYR61, CTGF, HOXA11, LOXL2, GREM1, POR, BMP2, EFEMP1, FRZB, RARA, SNAI2]
GO:0033280;response to vitamin D;7.0;0.9326813400603323;0.8172600352873667;9.548481544818586;74.55580141320215;6.375876246018314;0.002495315577434836;0.6769819729871445;[TGFB1, ABCB4, TNC, PTGS2, CXCL10, CD4, IL1B, SPP1, ALPL]
GO:0090235;regulation of metaphase plate congression;6.0;0.8259837884571596;0.7361122068187242;9.427853557029971;45.24164634670696;7.8311634786251565;0.001514197188386001;0.7236063770733796;[MAD1L1]
GO:0045907;positive regulation of vasoconstriction;8.0;0.8933024483968273;0.8216512241984136;9.57973408832269;103.52331479149503;6.280566066213989;0.003464832181136806;0.6961884407023742;[CAV1, PTAFR, F2R, AVPR1A, PTGS2, AKT1]
GO:0001570;vasculogenesis;4.0;0.8933024483968273;0.6966512241984136;9.292052015870908;21.066225782797595;5.6339389012889365;7.050676185779127E-4;0.5381198974168686;[YAP1, ADM, GJC1, TMEM100, HHEX, MYOCD, TGFB1, CAV1, TIE1, PTK2, TGFBR3, ENG]
GO:0006469;negative regulation of protein kinase activity;10.0;0.6835726970475526;0.7570273603846966;9.223059144383958;1097.0598301796;4.243684138952949;0.03671760522636433;0.6322632160784685;[PYCARD, PPP2R1A, AKT1, EPHB2, MEN1, PAQR3, PRKCD, TSC2, SFRP2, PRKAR1B, THY1, SOCS2, FLRT2, PRKAR2B, SFN, LYN, CAV1, PLK1, NR2F2, PTPRC, PKIG, CDKN1A, LRRC4, TNFAIP3, PTPN22, HHEX, DUSP10, LRRTM4, NUP62, DUSP2, MYOCD, DUSP1, BGN, IRAK3, GP1BA, SIRT1, DUSP6, DCN, CEACAM1, IL1B, LRRC19, CDKN2C, PODN, PTPN6, PKN1]
GO:0060744;mammary gland branching involved in thelarche;8.0;1.0;0.875;9.628524252492122;74.22212479985593;8.16763571524637;0.002484147721475594;0.7926932703116032;[TGFB1, PHB2]
GO:0000122;negative regulation of transcription by RNA polymerase II;11.0;0.6073376606709605;0.7360977826651425;8.793202583151634;1836.9481969605868;3.0544438328250214;0.0614810030062249;0.5886333519864981;[SPI1, EHMT2, SLA2, MYB, HOXA2, HOXA7, MEF2A, MEF2C, HOXB4, HOXB3, ATF3, GATA3, GATA1, PRDM16, ELANE, JUN, PLK1, FZD8, NR2F2, SNAI2, PKIG, EZH2, PAWR, PAX5, SIRT1, AES, MMP12, RARA, ASCL2, NR1H2, POU4F1, FOSB, TNF, DACH1, MEN1, TLE4, AEBP1, FOXO1, NACC2, WFS1, NFKB1, BCL6, CIITA, FHL2, FASLG, HHEX, RFC1, PEG3, CEBPB, RBBP8, E2F1, E2F7, PRRX1, KLF4, KLF8, KLF5, DNAJA3, UXT, ZNF608, EDNRB, SOX7, SOX4, HNF1B, IFI27, TWIST1, PCBP3, EGR1, BCL11A, ID1, SUV39H1, BMI1, XPO1, CD36, EDN1, IL1B, SATB2, CDX2, LOXL2, CHCHD3, CCNE1, TGFB1, CBX4, VDR, CAV1, NR4A2, BMP2, NR4A3, MXD1, MYOCD, IFNG, IRF7, FBP1, AURKB, SNCA, MEIS2]
GO:0010718;positive regulation of epithelial to mesenchymal transition;6.0;0.811012628672052;0.7286266269261705;9.377209824211215;170.70262580884207;5.9928839937622085;0.005713263263432726;0.6295966787287501;[TGFB1I1, TWIST1, LOXL2, EPB41L5, PDPN, TGFB2, TGFB1, AXIN2, COL1A1, BMP2, DAB2, IL1B, EZH2, ENG]
GO:0045591;positive regulation of regulatory T cell differentiation;10.0;0.8933024483968273;0.861892236059334;9.60254876608886;997.8066164740876;7.292166977892469;0.03339568948573388;0.7881627702307852;[TGFB1, DUSP10, BCL6, IFNG, LILRB2]
GO:0031659;positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle;13.0;1.0;0.9625549647676366;9.628524252492122;3325.2743974982595;7.8311634786251565;0.11129394153160196;0.8630410292508717;[AKT1]
GO:0032869;cellular response to insulin stimulus;8.0;1.0;0.875;9.628524252492122;462.69925393661634;5.334422371190153;0.015486127626965131;0.6478026081386739;[CYFIP1, AKT1, GHSR, CEACAM1, FOXO1, PAK1, SORBS1]
GO:0031536;positive regulation of exit from mitosis;9.0;1.0;0.896240625180289;9.628524252492122;562.0425168150831;8.16763571524637;0.018811057232375368;0.8139338954918922;[TGFB1, UBE2C, CDCA5, PHB2]
GO:0097421;liver regeneration;6.0;1.0;0.8231203125901445;9.628524252492122;47.21654787453615;6.250713103064308;0.0015802953652264606;0.6427820713687392;[IL10, CEBPB, PCNA, TGFB1, IHH, SULF2, NFKBIA, HMOX1, EZH2]
GO:0032868;response to insulin;7.0;0.9326813400603323;0.8172600352873667;9.541512875502493;74.03337757263446;4.800339885259895;0.0024778305216419678;0.5964089702280253;[CYFIP1, ADM, SESN3, AKT1, IL10, GHSR, CAD, SIRT1, CEACAM1, TLR2, RETN, FOXO1, PAK1, PLN, LYN, EGR1, EGR2, SORT1, SORBS1]
GO:0010716;negative regulation of extracellular matrix disassembly;7.0;1.0;0.8509193652572005;9.628524252492122;86.13995449886744;8.390779266560578;0.002883026756151129;0.7800242071602487;[DPP4, CST3, TGFB1, FAP]
GO:0032740;positive regulation of interleukin-17 production;6.0;0.8653626801206646;0.7558016526504768;9.427853557029971;65.23665507211369;7.212124270218933;0.002183412136085803;0.6919486831672181;[TGFB1, IL23A, PRKCQ, NOD2, LY9, MYD88]
GO:0010830;regulation of myotube differentiation;7.0;0.7369933605727446;0.7194160455435727;9.0689084645567;30.04387765457723;5.769740442447999;0.0010055415473642492;0.6459841598043611;[CXCL9, RBM38, MYOCD, TNFSF14, FLT3LG, MAPK14, CXCL10, CEACAM5, SIK1]
GO:0070306;lens fiber cell differentiation;5.0;1.0;0.7902410118609202;9.628524252492122;24.20171999872632;7.212124270218933;8.100097882234571E-4;0.659069382437994;[TGFB1, SLC7A11]
GO:0031532;actin cytoskeleton reorganization;6.0;1.0;0.8231203125901445;9.628524252492122;32.01253927882412;5.788089581116195;0.001071430880247358;0.6191234829421188;[NRP1, ANTXR1, PAK1, FLNA, CXADR, ANXA1, GAB1, KIT]
GO:0035458;cellular response to interferon-beta;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;7.004484905440688;0.0027327542132076126;0.6813299963962409;[CDC34]
GO:1903351;cellular response to dopamine;8.0;1.0;0.875;9.628524252492122;545.6259493406901;7.138016298065211;0.018261609492958953;0.7400384854347593;[LRRK2, ID1, DNM2]
GO:0031098;stress-activated protein kinase signaling cascade;6.0;0.7980440201809971;0.722142322680643;9.193206181234276;55.4262366053078;5.142344639450834;0.0018550662588052154;0.5861000565951415;[TNF, CHUK, STRADB, NOD2, MAP2K6, MAPK14, NFKB1, MAPK13]
GO:0045599;negative regulation of fat cell differentiation;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;114.62387697121986;5.948432231191374;0.0038363580074348307;0.6273234135236593;[TGFB1I1, GATA3, TNF, FOXO1, E2F1, TGFB1, JAG1, SORT1, SIRT1, IL6]
GO:0007565;female pregnancy;3.0;1.0;0.6981203125901445;9.628524252492122;32.8060485501291;5.299736813202263;0.0010979889214459554;0.4691490996802742;[IL1RN, ADM, PRL, THBD, TGFB1, IGFBP5, CAD, FOS, ADCYAP1, CLDN4, PNOC, RARA, FOSB]
GO:0006355;regulation of transcription, DNA-templated;9.0;0.4043225613388953;0.5984019058497367;6.838723401371219;245.35026186902695;1.5478292109445575;0.008211652463856259;0.4753966830094131;[NUP107, SPI1, SLA2, SPIB, AKT1, MNX1, ATF3, CDCA7, GATA3, GATA1, JUN, JAG1, JUP, NR2F2, PKIG, HOXC10, CHAF1B, FOS, MMP12, MED23, PTAFR, SPP1, ZNF467, CASP8AP2, ATAD2, NOC3L, CENPF, PKN1, LGR4, GMNN, EFEMP1, BLM, ZNF423, CIITA, ITGB2, HHEX, E2F1, E2F2, E2F5, E2F7, POU2AF1, SMARCAL1, TNFSF11, FBXO5, BTK, TGFA, PKHD1, EGR1, EGR2, EGR3, POLA1, ECM1, IL10, SYK, IL1B, KIT, DEPDC1, YAP1, PCNA, NR3C2, LOXL2, CARD11, HTRA1, CAV1, TCF4, MXD1, FBN1, TNFAIP3, LYL1, MYOCD, NUP133, IRAK3, ETV1, GREM1, ELF3, FBP1, RRM2, CD4, PHB2, PRKCQ, NUP85, PRDM16, HMOX1, NFE2, PLK1, SNAI2, CDKN1A, ZNF367, RARA, NR1I2, ASCL2, EPCAM, NR1H2, ELP4, FOSB, PF4, PLXND1, TNF, CLU, TLE4, MAP2K2, AEBP1, MAP2K6, DAB2, COPS5, BCL6, BCL3, CCDC22, SLC26A3, CYR61, LBH, EMILIN1, RFC1, TFDP1, XCL1, CEBPB, CEBPE, NLRC4, NOD2, ABLIM3, POLR2K, POLR2L, PML, DNAJA3, PPIL4, PPP2R1A, RPS6KA1, FLT3LG, NIF3L1, IL23A, SIK1, TWIST1, LIF, TOP2A, AHCTF1, IFNA2, PRL, XPO1, EDN1, CBFA2T3, VAV1, MLF2, HCK, TLR6, TLR4, TLR2, PURA, GRHL2, CD40LG, HOXA11, HOXA10, FANCD2, NLRP3, CBX4, KDM5D, SLC40A1, H2AFX, DCN, DNM2, PFDN5, LTF, SNCA, LUM, RBMX, PID1, EHMT2, MEF2A, MEF2C, PADI2, PADI4, HACE1, COL1A1, EZH2, ACTL6A, SIRT1, PSMA6, CKS2, FSTL1, BTAF1, STAT4, FLNA, USP9Y, PSMC6, PSMC2, CCNT2, RUVBL2, RUVBL1, ADCYAP1, S100A8, MAZ, TNFRSF11A, FOXO1, NFKB1, CXCL10, MYD88, FHL2, FASLG, PPP1R12A, PEG3, BIRC5, BDP1, LRP2, PRRX1, CCNH, UXT, TMPO, HNF1B, EREG, SFRP4, SFRP2, IFI27, PCBP3, ZNF700, OR7D2, ID1, CD28, CD40, SUV39H1, HNF4G, PTPRK, BRCA1, BRCA2, PCSK6, BMI1, CD3D, HNF4A, CD36, RGMA, SATB2, CD74, NLRP12, FOXA3, IL17A, FOXA2, CD86, CD80, IHH, CCNE1, CALCA, VDR, HMGA1, INHBA, IL6, BMP2, HMGB2, ARHGEF10L, AFF3, NUP62, YWHAH, DDX58, CCNA2, PSRC1, IRF7, CREB5, TAF9, AURKB, EGF, MAPK14, MAPK13, NUP35, TAF5, RAN, EHF, SERPINE1, HOXA9, MYB, HOXA3, HOXA2, CYP1B1, HOXA7, HOXA5, HOXA4, HOXB9, HOXB4, HOXB3, HOXB2, MAML3, HOXB7, HOXB6, HOXB5, S100A12, ELANE, NKX2-3, FZD1, FZD5, FZD8, CDC6, TGFB1I1, HAVCR2, BRD2, ANXA3, NFAM1, PAWR, PAX5, PAX2, AES, ENG, GTF2H1, SULF1, POU4F1, PYCARD, DACH1, CDH1, MEN1, F2R, NACC2, WFS1, HOPX, CNOT3, MAFF, CHUK, TRAF1, SMARCD3, RBBP8, ZNF503, IRX3, KLF4, KLF1, KLF8, KLF5, MNDA, ZNF608, EDNRB, CHEK1, DPF3, SOX7, SOX4, SLC11A1, EBF1, RUNX2, PFN1, BEX1, SP140, NHLH2, BCL11B, BCL11A, RHOG, RHOH, MDFIC, TFEC, SGK1, CDX2, CDX1, LILRB1, CAMK4, CAMK1, ARID4A, ARID4B, CHCHD3, BASP1, ADRB2, TGFB2, TGFB1, NR4A2, NFKBIA, NR4A1, LIN28A, NR4A3, FEV, JMY, CREBZF, TMEM100, CKAP2, TGFBR3, IFNG, CAMK2D, DLL1, HSPD1, MEIS2, MEIS1]
GO:0046326;positive regulation of glucose import;8.0;0.9326813400603323;0.8413406700301662;9.548481544818586;84.68372616907679;5.970411137910149;0.0028342881044734467;0.6803271032452366;[PAK1, AKT1, MEF2A, SORBS1, MAPK14]
GO:0006479;protein methylation;8.0;0.5860072649471136;0.6680036324735568;8.391761625343195;206.79845698774034;4.917261223318797;0.006921358248851439;0.6264689676365554;[, EHMT2, SUV39H1, ARID4A, ARID4B, FBL, SNRPD3, MEN1, GSPT1, PRDM16, EZH2]
GO:0046329;negative regulation of JNK cascade;12.0;0.9326813400603323;0.9144609826203107;9.607904965289386;1764.4523437695266;6.280566066213989;0.05905463204195212;0.7693087532925187;[PTPN22, DUSP10, SFRP2, AKT1, MEN1]
GO:1903911;positive regulation of receptor clustering;8.0;0.8933024483968273;0.8216512241984136;9.474373572664863;110.66472907477197;8.16763571524637;0.0037038488903424972;0.7926932703116032;[TGFB1]
GO:0030316;osteoclast differentiation;6.0;0.9326813400603323;0.7894609826203107;9.510741216835738;47.07409398820286;6.375876246018314;0.0015755275618510598;0.6491829203200885;[CSF1R, TGFB1, FCER1G, TFRC, TREM2, TNFRSF11A, MAPK14, TNF, OSCAR, TNFSF11, EPHA2]
GO:0098884;postsynaptic neurotransmitter receptor internalization;9.0;1.0;0.896240625180289;9.628524252492122;106.27993511699428;8.390779266560578;0.00355709378263404;0.8253454670833372;[DNM2]
GO:0051232;meiotic spindle elongation;4.0;1.0;0.75;9.628524252492122;45.03457221597044;9.777073627680469;0.0015072666035848682;0.75;[PPP2R1A]
GO:0043066;negative regulation of apoptotic process;7.0;0.5640623033008358;0.6329505169076184;7.792313020693233;81.07407142393629;2.9735683700721314;0.0027134762086319553;0.5029877899877601;[SERPINE1, PHB2, AKT1, PROK2, IER3, MEF2C, DAPK1, PRKCD, CLDN7, PRKCQ, GATA3, SLC30A10, GATA1, FIGNL1, HMOX1, SFN, NCKAP1L, BARD1, JUN, PLK2, PLK1, AZU1, SNAI2, CDKN1A, CHL1, TIMP1, ANXA1, DUSP1, ANXA5, SERPINB9, SIRT1, PAX2, RARA, PTGS2, UNG, NTF3, FLNA, CCL19, CCL21, GABRA5, POU4F1, FABP1, PF4, TNF, CLU, CLEC5A, F2R, ADCYAP1, MSH2, CSF1R, BLM, CORO1A, FOXO1, SOCS2, WFS1, TNFRSF10C, TNFRSF10B, DHCR24, NFKB1, DAB2, CXCL12, COPS5, BCL6, BCL3, CDK1, MYD88, BCL2L1, LRRK2, FHL2, FASLG, CYR61, TNFRSF1B, ADAMTS20, BIRC5, CX3CR1, CEBPB, LRP1, NLRC4, NOD2, CCL5, CCL2, FYN, TIE1, KLF4, IL2RB, IL1RN, SLC46A2, AQP1, LGALS3, TCL1A, EDNRB, RPS6KA1, EPHB2, EPHB1, FLT3LG, HNF1B, MIF, BTC, POR, SFRP2, EPHA3, NAIP, EPHA2, TWIST1, PKHD1, EGR3, BCL11B, TNFSF14, PTK2, VNN1, ID1, CD28, NRP1, BRCA1, CTSH, CCR7, CCR5, IL10, EDN1, FCER1G, STRADB, HCK, RNF144B, CEACAM6, IL1B, CEACAM5, KIT, YAP1, IFI6, GNAI2, CXCR2, PDPN, CTNNA1, CD74, LILRB1, CD40LG, GRINA, MAD2L1, IHH, MPO, COMP, ARHGDIA, PDGFRB, GHSR, PDGFRA, C5AR1, PSEN2, STIL, CBX4, CAV1, NR4A2, NFKBIA, VIL1, IL6, NR4A3, TNFAIP8, HMGB2, SLC40A1, TNFAIP3, NUP62, MYOCD, PLAUR, MMP9, GREM1, NDUFS3, IRF7, LTF, BCL2A1, TAF9, DLL1, THBS1, AURKB, HSPD1, SNCA, TEK]
GO:0043065;positive regulation of apoptotic process;7.0;0.5587538620495764;0.6302962962819887;7.806911820114386;80.91235068524658;3.3969510907807043;0.0027080635610472266;0.5246396020141064;[MYB, AKT1, CYP1B1, HOXA5, MEF2C, DAPK1, PRKCD, ATF3, HMOX1, SFN, PLCG1, BARD1, LYN, JUN, NOX4, NOX1, ADM, CTLA4, TIMP3, ANXA1, DUSP1, PAWR, SIRT1, F3, DUSP6, AES, PTGS2, FGD3, FGD4, FRZB, CASP8AP2, GSN, BIK, G0S2, POU4F1, TNF, CTGF, PYCARD, IGFBP3, F2R, MELK, MAL, S100A8, CD274, FOXO1, NACC2, MAP2K6, TNFRSF10B, BCL6, BCL2L1, PLEKHF1, FASLG, CYR61, ITGA4, TFDP1, LCK, NLRC4, CCL5, E2F1, CCL2, PML, P2RX1, MNDA, PPP2R1A, SOX7, SOX4, TIAM2, SFRP4, SFRP2, CDC34, IFI27, SIK1, INPP5D, TP53BP2, TNFSF12, ITM2C, TOP2A, CD40, CTSZ, CTSH, IL10, VAV1, IL1B, CXCR2, CTNNA1, SORT1, LILRB1, PPP1CA, NLRP12, CD40LG, FAP, DLC1, PDGFRB, NLRP3, ECT2, TGFB2, TGFB1, VDR, CAV1, INHBA, EIF2S1, IL6, BMP2, NR4A3, JMY, UBE2M, TNFAIP8, YWHAH, ARHGEF12, PLAUR, MMP9, DNM2, IFNG, LTA, CAMK2D, BCL2A1, THBS1, HSPD1, CNR1, SNCA, HSPE1, LTBR]
GO:0006909;phagocytosis;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;28.437470009997963;5.618190544320798;9.517765291732001E-4;0.610434838299289;[ITGB3, NCF4, ICAM3, ITGAL, CD36, ANXA1, CD93, ANXA3, SLC11A1, DNM2, PECAM1, RARA, PRTN3, CD302, LRP1, CEBPE, PLD4, CORO1A, CD14, ELANE, MARCO]
GO:0031641;regulation of myelination;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;42.055147161688105;6.250713103064308;0.001407547928326502;0.6427820713687392;[RARA, AKT1, WASF3]
